Agency Name: Department of Health and Environmental Control

Statutory Authority: 13-7-40 et seq.

Document Number: 5036

Final in State Register Volume and Issue: 45/5

Proposed in State Register Volume and Issue: 45/2

Final in State Register Volume and Issue: 45/5

Status: Final

Subject: Radioactive Materials (Title A)

History: 5036

By Date Action Description Jt. Res. No. Expiration Date

- 02/26/2021 Proposed Reg Published in SR

- 05/28/2021 Final to comply with Federal

 Law, exempt GA review

- 05/28/2021 Effective Date unless otherwise

 provided for in the Regulation

Document No. 5036

**DEPARTMENT OF HEALTH AND ENVIRONMENTAL CONTROL**

CHAPTER 61

Statutory Authority: 1976 Code Sections 13‑7‑40 et seq.

61‑63. Radioactive Materials (Title A)*.*

**Synopsis:**

Pursuant to S.C. Code Sections 13‑7‑40 et seq., the Department of Health and Environmental Control (“Department”) is responsible for regulatory and licensing standards, disposal, use, reports, storage, and inspections relating to various uses of radioactive materials. The Department amends R.61‑63 to incorporate federal law as required to maintain South Carolina’s status with the United States Nuclear Regulatory Commission (“NRC”) as an Agreement State.

The Administrative Procedures Act, S.C. Code Section 1-23-120(H)(1), exempted these amendments from General Assembly review, as the Department promulgates these amendments for compliance with federal law.

The Department had a Notice of Drafting published in the October 23, 2020, *South Carolina State Register.*

**Instructions:**

Amend R.61-63 pursuant to each instruction provided with the text of the amendments below.

**Text:**

61‑63. Radioactive Materials (Title A).

(Statutory Authority: Section 13‑7‑40 et seq., as amended, of the 1976 Code, namely the Atomic Energy and Radiation Control Act)

**Amend the following Table of Contents sections to read:**

SUBPART B General Administrative Requirements

RHA

4.13 Authority and Responsibilities for the Radiation Protection Program

4.14 Radiation Protection Program Changes

4.15 Supervision

4.17 Written Directives

4.18 Procedures for Administrations Requiring a Written Directive

4.19 Suppliers for Sealed Sources or Devices for Medical Use

4.20 Training for Radiation Safety Officers and Associate Radiation Safety Officer

4.21 Training for an Authorized Medical Physicist

4.22 Training for an Authorized Nuclear Pharmacist

4.23 Training for Experienced Radiation Safety Officer, Teletherapy or Medical Physicist, Authorized

 User, and Nuclear Pharmacist

4.24 Recentness of Training

SUBPART D Unsealed Radioactive Material—Written Directive Not Required

RHA

4.35 Use of Unsealed Radioactive Material for Uptake, Dilution, and Excretion Studies for Which a

 Written Directive is not Required

4.36 Training for Uptake, Dilution, and Excretion Studies

4.37 Use of Unsealed Radioactive Material for Imaging and Localization Studies for Which a Written

 Directive is not Required

4.38 Permissible Molybdenum‑99, Strontium‑82, and Strontium‑85 Concentrations

4.39 Training for Imaging and Localization Studies

SUBPART E Unsealed Radioactive Material—Written Directive Required

RHA

4.40 Use of Unsealed Radioactive Material for Which a Written Directive is Required

4.41 Safety Instruction

4.42 Safety Precautions

4.43 Training for Use of Unsealed Radioactive Material for Which a Written Directive is Required

4.44 Training for the Oral Administration of Sodium Iodide I‑131 Requiring a Written Directive in

 Quantities Less Than or Equal to 1.22 Gigabecquerels (33 Millicuries)

4.45 Training for the Oral Administration of Sodium Iodide I‑131 Requiring a Written Directive in

 Quantities Greater Than 1.22 Gigabecquerels (33 Millicuries)

SUBPART F Manual Brachytherapy

RHA

4.46 Use of Sources for Manual Brachytherapy

4.47 Surveys After Source Implant and Removal

4.48 Brachytherapy Sources Accountability

4.49 Safety Instruction

4.50 Safety Precautions

4.51 Calibration Measurements of Brachytherapy Sources

4.52 Strontium‑90 Sources for Ophthalmic Treatments

4.53 Therapy‑Related Computer Systems

4.54 Training for Use of Manual Brachytherapy Sources

4.55 Training for Ophthalmic Use of Strontium‑90

SUBPART G Sealed Sources for Diagnosis

RHA

4.56 Use of Sealed Sources and Medical Devices for Diagnosis

4.57 Training for Use of Sealed Sources for Diagnosis

SUBPART H Photon Emitting Remote Afterloader Units, Teletherapy Units, and Gamma

Stereotactic Radiosurgery Units

RHA

4.58 Use of a Sealed Source in a Remote Afterloader Unit, Teletherapy Unit, or Gamma Stereotactic

 Radiosurgery Unit

4.59 Surveys of Patients and Human Research Subjects Treated With a Remote Afterloader Unit

4.60 Installation, Maintenance, Adjustment, and Repair

4.61 Safety Procedures and Instructions for Remote Afterloader Units, Teletherapy Units, and Gamma

 Stereotactic Radiosurgery Units

4.62 Safety Precautions for Remote Afterloader Units, Teletherapy Units, and Gamma Stereotactic

 Radiosurgery Units

4.63 Dosimetry Equipment

4.64 Full Calibration Measurements on Teletherapy Units

4.65 Full Calibration Measurements on Remote Afterloader Units

4.66 Full Calibration Measurements on Gamma Stereotactic Radiosurgery Units

4.67 Periodic Spot‑Checks for Teletherapy Units

4.68 Periodic Spot‑Checks for Remote Afterloader Units

4.69 Periodic Spot‑Checks for Gamma Stereotactic Radiosurgery Units

4.70 Additional Technical Requirements for Mobile Remote Afterloader Units

4.71 Radiation Surveys

4.72 Full‑inspection Servicing for Teletherapy and Gamma Stereotactic Radiosurgery Units

4.73 Therapy‑Related Computer Systems

4.74 Training for Use of Remote Afterloader Units, Teletherapy Units, and Gamma Stereotactic

 Radiosurgery Units

SUBPART L Records

RHA

4.89 Records of Authority and Responsibilities for Radiation Protection Programs

4.90 Records of Radiation Protection Program Changes

4.91 Records of Written Directives

4.92 Records For Procedures For Administrations Requiring a Written Directive

4.93 Records of Calibrations of Instruments Used to Measure the Activity of Unsealed Radioactive

 Material

4.94 Records of Radiation Survey Instrument Calibrations

4.95 Records of Dosages of Unsealed Radioactive Material For Medical Use

4.96 Records of Leaks Tests and Inventory of sealed Sources and Brachytherapy Sources

4.97 Records of Surveys For Ambient Radiation Exposure Rate

4.98 Records of the Release of Individuals Containing Unsealed Radioactive Material or Implants

 Containing Radioactive Material

4.99 Records of Mobile Medical Services

4.100 Records of Decay‑in‑Storage

4.101 Records of Molybdenum‑99 Concentrations

4.102 Records of Safety Instruction

4.103 Records of Surveys After Source Implant and Removal

4.104 Records of Brachytherapy Source Accountability

4.105 Records of Calibration Measurements of Brachytherapy Sources

4.106 Records of Decay of Strontium‑90 Sources for Ophthalmic Treatments

4.107 Records of Installation, Maintenance, Adjustment, and Repair of Remote Afterloader Units,

 Teletherapy Units, and Gamma Stereotactic and Radiosurgery Units

4.108 Records of Safety Procedures

4.109 Records of Dosimetry Equipment Used with Remote Afterloader Units, Teletherapy Units, and

 Gamma Stereotactic Radiosurgery Units

4.110 Records of Teletherapy, Remote Afterloader, and Gamma Stereotactic Radiosurgery Full

 Calibrations

4.111 Records of Periodic Spot‑Checks for Teletherapy Units

4.112 Records of Periodic Spot‑Checks for Remote Afterloader Units

4.113 Records of Periodic Spot‑Checks for Gamma Stereotactic Radiosurgery Units

4.114 Records of Additional Technical Requirements for Mobile Remote Afterloader Units

4.115 Records of Surveys of Therapeutic Treatment Units

4.116 Records of Full‑inspection Servicing for Teletherapy and Gamma Stereotactic Radiosurgery

 Units

SUBPART M Reports

RHA

4.117 Report and Notification of a Medical Event

4.118 Report and Notification of a Dose to an Embryo/Fetus or a Nursing Child

4.119 Report of a Leaking Source

4.120 Report and Notification for an Eluate Exceeding Permissible Molybdenum‑99, Strontium‑82, and Strontium‑85 Concentrations

**Amend 2.7.5.1.4 to read:**

 2.7.5.1.4 The applicant commits to the following labeling requirements:

**Amend 2.7.5.2.5.1 to read:**

 2.7.5.2.5.1 A copy of each individual’s certification by a specialty board whose certification process has been recognized by the Nuclear Regulatory Commission or an Agreement State as specified in RHA 4.22.1; or

**Amend 2.7.5.4 to read:**

 2.7.5.4 A licensee shall satisfy the labeling requirements in paragraph 2.7.5.1.4 of this section.

 2.7.5.5 Nothing in this section relieves the licensee from complying with applicable FDA, other Federal, and State requirements governing radioactive drugs.

**Amend 2.10.8 to read:**

 2.10.8 Each licensee preparing technetium‑99m radiopharmaceuticals from molybdenum‑99/technetium‑99m generators or rubidium‑82 from strontium‑82/rubidium‑82 generators shall test the generator eluates for molybdenum‑99 breakthrough or strontium‑82 and strontium‑85 contamination, respectively, in accordance with RHA 4.38. The licensee shall record the results of each test and retain each record for 3 years after the record is made. The licensee shall report the results of any test that exceeds the permissible concentration listed in 4.38.1 of this chapter at the time of generator elution, in accordance with RHA 4.120 of this chapter.

**Add 2.10.10:**

 2.10.10 Conditions of licenses.

2.10.10.1 Each license shall contain and be subject to the following conditions:

2.10.10.1.1 [Reserved]

2.10.10.1.2 No right to the special nuclear material shall be conferred by the license except as defined by the license;

2.10.10.1.3 Neither the license nor any right under the license shall be assigned or otherwise transferred in violation of the provisions of the Act;

2.10.10.1.4 [Reserved]

2.10.10.1.5 [Reserved]

2.10.10.1.6 [Reserved]

2.10.10.1.7 [Reserved]

2.10.10.1.8 The license shall be subject to and the licensee shall observe, all applicable rules, regulations, and orders of the Department.

 2.10.10.1.9 Notification of Bankruptcy.

 2.10.10.1.9.1 Each licensee shall notify the Department, in writing, immediately following the filing of a voluntary or involuntary petition for bankruptcy under any Chapter of Title 11 (Bankruptcy) of the United States Code by or against:

 2.10.10.1.9.1.1 The licensee;

 2.10.10.1.9.1.2 An entity (as that term is defined in 11 U.S.C. 101(14)) controlling the licensee or listing the license or licensee as property of the estate; or

 2.10.10.1.9.1.3 An affiliate (as that term is defined in 11 U.S.C. 101(a)) of the licensee.

 2.10.10.1.9.2 The notification required in 2.10.10.1.9.1 must indicate:

 2.10.10.1.9.2.1 The bankruptcy court in which the petition for bankruptcy was filed; and

 2.10.10.1.9.2.2 The date of the filing of the petition.

**Amend 4.2 to read:**

 4.2.1 “Address of use” means the building or buildings that are identified on the license and where radioactive material may be received, prepared, used, or stored.

 4.2.2 “Agreement State” means any State with which the Nuclear Regulatory Commission (hereafter referred to as NRC) or the Atomic Energy Commission has entered into an effective agreement under subsection 274b of the Atomic Energy Act of 1954, as amended.

 4.2.3 “Area of use” means a portion of an address of use that has been set aside for the purpose of receiving, preparing, using, or storing radioactive material.

 4.2.4 "Associate Radiation Safety Officer" means an individual who—

 4.2.4.1 Meets the requirements in RHA 4.20 and RHA 4.24; and

 4.2.4.2 Is currently identified as an Associate Radiation Safety Officer for the types of use of radioactive material for which the individual has been assigned duties and tasks by the Radiation Safety Officer on—

 4.2.4.2.1 A specific medical use license issued by the Nuclear Regulatory Commission or an Agreement State; or

 4.2.4.2.2 A medical use permit issued by a Nuclear Regulatory Commission master material licensee.

 4.2.5 “Authorized medical physicist” means an individual who—

 4.2.5.1 Meets the requirements in RHA 4.21.1 and RHA 4.24; or

 4.2.5.2 Is identified as an authorized medical physicist or teletherapy physicist on—

 4.2.5.2.1 A specific medical use license issued by the NRC or an Agreement state;

 4.2.5.2.2 A medical use permit issued by an NRC master material licensee;

 4.2.5.2.3 A permit issued by an NRC or Agreement State broad scope medical use licensee; or

 4.2.5.2.4 A permit issued by an NRC master material license broad scope medical use permittee.

 4.2.6 “Authorized nuclear pharmacist” means a pharmacist who—

 4.2.6.1 Meets the requirements in RHA 4.22.1 and RHA 4.24; or

 4.2.6.2 Is identified as an authorized nuclear pharmacist on—

 4.2.6.2.1 A specific license issued by the NRC or Agreement State that authorizes medical use or the practice of nuclear pharmacy; or

 4.2.6.2.2 A permit issued by an NRC master material licensee that authorizes medical use or the practice of nuclear pharmacy; or

 4.2.6.2.3 A permit issued by an NRC or Agreement State broad scope medical use licensee that authorizes medical use or the practice of nuclear pharmacy; or

 4.2.6.2.4 A permit issued by an NRC master material license broad scope medical use permittee that authorizes medical use or the practice of nuclear pharmacy; or

 4.2.6.3 Is identified as an authorized nuclear pharmacist by a commercial nuclear pharmacy that has been authorized to identify authorized nuclear pharmacists; or

 4.2.6.4 Is designated as an authorized nuclear pharmacist in accordance with RHA 2.7.5.2.4.

 4.2.7 “Authorized user” means a physician, dentist, or podiatrist who—

 4.2.7.1 Meets the requirements in RHA 4.24 and RHA 4.36.1, RHA 4.39.1, RHA 4.43.1, RHA 4.44.1.1, RHA 4.45.1.1, RHA 4.54.1.1, RHA 4.57.1.1, or RHA 4.74.1.1; or

 4.2.7.2 Is identified as an authorized user on—

 4.2.7.2.1 An NRC or Agreement State license that authorizes the medical use of radioactive material;

 4.2.7.2.2 A permit issued by an NRC master material licensee that is authorized to permit the medical use of radioactive material;

 4.2.7.2.3 A permit issued by an NRC or Agreement State specific licensee of broad scope that is authorized to permit the medical use of radioactive material; or

 4.2.7.2.4 A permit issued by an NRC master material license broad scope permittee that is authorized to permit the medical use of radioactive material.

 4.2.8 “Brachytherapy” means a method of radiation therapy in which sources are used to deliver a radiation dose at a distance of up to a few centimeters by surface, intracavitary, intraluminal, or interstitial application.

 4.2.9 “Brachytherapy source” means a radioactive source or a manufacturer‑assembled source train or a combination of these sources that is designed to deliver a therapeutic dose within a distance of a few centimeters.

 4.2.10 “Client’s address” means the area of use or a temporary job site for the purpose of providing mobile medical service in accordance with RHA 4.33.

 4.2.11 “Consortium” means an association of medical use licensees and a PET radionuclide production facility in the same geographical area that jointly own or share in the operation and maintenance cost of the PET radionuclide production facility that produces PET radionuclides for use in producing radioactive drugs within the consortium for noncommercial distributions among its associated members for medical use. The PET radionuclide production facility within the consortium must be located at an educational institution or a Federal facility or a medical facility.

 4.2.12 “Dedicated check source” means a radioactive source that is used to assure the constant operation of a radiation detection or measurement device over several months or years.

 4.2.13 “Dentist” means an individual licensed by a State or Territory of the United States, the District of Columbia, or the Commonwealth of Puerto Rico to practice dentistry.

 4.2.14 “High dose‑rate remote afterloader,” as used in this part, means a brachytherapy device that remotely delivers a dose rate in excess of 12 gray (1200 rads) per hour at the point or surface where the dose is prescribed.

 4.2.15 “Low dose‑rate remote afterloader,” as used in this part, means a brachytherapy device that remotely delivers a dose rate of less than or equal to 2 gray (200 rads) per hour at the point or surface where the dose is prescribed.

 4.2.16 “Management” means the chief executive officer or other individual having the authority to manage, direct, or administer the licensee’s activities, or those persons’ delegate or delegates.

 4.2.17 “Manual brachytherapy,” as used in this part, means a type of brachytherapy in which the brachytherapy sources (e.g., seeds, ribbons) are manually placed topically on or inserted either into the body cavities that are in close proximity to a treatment site or directly into the tissue volume.

 4.2.18 “Medical event” means an event that meets the criteria in RHA 4.117.1.

 4.2.19 “Medical institution” means an organization in which more than one medical discipline is practiced.

 4.2.20 “Medical use” means the intentional internal or external administration of radioactive material or the radiation from radioactive material to patients or human research subjects under the supervision of an authorized user.

 4.2.21 “Medium dose‑rate remote afterloader,” as used in this part, means a brachytherapy device that remotely delivers a dose rate of greater than 2 gray (200 rads), but less than 12 gray (1200 rads) per hour at the point or surface where the dose is prescribed.

 4.2.22 “Mobile medical service” means the transportation of radioactive material to and its medical use at the client’s address.

 4.2.23 “Ophthalmic physicist” means an individual who—

 4.2.23.1 Meets the requirements in RHA 4.52.1.2 and RHA 4.24; and

 4.2.23.2 Is identified as an ophthalmic physicist on a—

 4.2.23.2.1 Specific medical use license issued by the Nuclear Regulatory Commission or an Agreement State;

 4.2.23.2.2 Permit issued by a Nuclear Regulatory Commission or Agreement State broad scope medical use licensee;

 4.2.23.2.3 Medical use permit issued by a Nuclear Regulatory Commission master material licensee; or

 4.2.23.2.4 Permit issued by a Nuclear Regulatory Commission master material licensee broad scope medical use permittee.

 4.2.24 “Output” means the exposure rate, dose rate, or a quantity related in a known manner to these rates from a brachytherapy source or a teletherapy, remote afterloader, or gamma stereotactic radiosurgery unit for specified set of exposure conditions.

 4.2.25 “Patient intervention” means actions by the patient or human research subject, whether intentional or unintentional, such as dislodging or removing treatment devices or prematurely terminating the administration.

 4.2.26 “Pharmacist” means an individual licensed by a State or Territory of the United States, the District of Columbia, or the Commonwealth of Puerto Rico to practice pharmacy.

 4.2.27 “Physician” means a medical doctor or doctor of osteopathy licensed by a State or Territory of the United States, the District of Columbia, or the Commonwealth of Puerto Rico to prescribe drugs in the practice of medicine.

 4.2.28 “Podiatrist” means an individual licensed by a State or Territory of the United States, the District of Columbia, or the Commonwealth of Puerto Rico to practice podiatry.

 4.2.29 “Positron Emission Tomography (PET) radionuclide production facility” means a facility operating a cyclotron or accelerator for the purpose of producing PET radionuclides.

 4.2.30 “Preceptor” means an individual who provides, directs or verifies the training and experience required for an individual to become an authorized user, an authorized medical physicist, an authorized nuclear pharmacist, or a Radiation Safety Officer.

 4.2.31 “Prescribed dosage” means the specified activity or range of activity of unsealed radioactive material as documented—

 4.2.31.1 In a written directive; or

 4.2.31.2 In accordance with the directions of the authorized user for procedures performed pursuant to RHA 4.35 and 4.37.

 4.2.32 “Prescribed dose” means—

 4.2.32.1 For gamma stereotactic radiosurgery, the total dose as documented in the written directive;

 4.2.32.2 For teletherapy, the total dose and dose per fraction as documented in the written directive;

 4.2.32.3 For manual brachytherapy, either the total source strength and exposure time or the total dose, as documented in the written directive; or

 4.2.32.4 For remote brachytherapy afterloaders, the total dose and dose per fraction as documented in the written directive.

 4.2.33 “Pulsed dose‑rate remote afterloader,” as used in this part, means a special type of remote afterloading brachytherapy device that uses a single source capable of delivering dose rates in the “high dose‑rate” range, but—

 4.2.33.1 Is approximately one‑tenth of the activity of typical high dose‑rate remote afterloader sources; and

 4.2.33.2 Is used to simulate the radiobiology of a low dose‑rate treatment by inserting the source for a given fraction of each hour.

 4.2.34 “Radiation Safety Officer” means an individual who—

 4.2.34.1 Meets the requirements in RHA 4.20.1 or 4.20.3 and RHA 4.24; or

 4.2.34.2 Is identified as a Radiation Safety Officer on—

 4.2.34.2.1 A specific medical use license issued by the NRC or Agreement State; or

 4.2.34.2.2 A medical use permit issued by an NRC master material licensee.

 4.2.35 “Sealed source” means any radioactive material that is encased in a capsule designed to prevent leakage or escape of the radioactive material.

 4.2.36 “Sealed Source and Device Registry” means the national registry that contains all the registration certificates, generated by both NRC and the Agreement States, that summarize the radiation safety information for the sealed sources and devices and describe the licensing and use conditions approved for the product.

 4.2.37 “Stereotactic radiosurgery” means the use of external radiation in conjunction with a stereotactic guidance device to very precisely deliver a therapeutic dose to a tissue volume.

 4.2.38 “Structured educational program” means an educational program designed to impart particular knowledge and practical education through interrelated studies and supervised training.

 4.2.39 “Teletherapy,” as used in this part, means a method of radiation therapy in which collimated gamma rays are delivered at a distance from the patient or human research subject.

 4.2.40 “Temporary job” means a location where mobile medical services are conducted other than those location(s) of use authorized on the license.

 4.2.41 “Therapeutic dosage” means a dosage of unsealed radioactive material that is intended to deliver a radiation dose to a patient or human research subject for palliative or curative treatment.

 4.2.42 “Therapeutic dose” means a radiation dose delivered from a source containing radioactive material to a patient or human research subject for palliative or curative treatment.

 4.2.43 “Treatment site” means the anatomical description of the tissue intended to receive a radiation dose, as described in a written directive.

 4.2.44 “Type of use” means use of radioactive material under RHA 4.35, 4.37, 4.40, 4.46, 4.56 4.58 or 4.88.

 4.2.45 “Unit dosage” means a dosage prepared for medical use for administration as a single dosage to a patient or human research subject without any further manipulation of the dosage after it is initially prepared.

 4.2.46 “Written directive” means an authorized user’s written order for the administration of radioactive material or radiation from radioactive material to a specific patient or human research subject, as specified in RHA 4.17.

**Amend 4.7.2.1 to read:**

 4.7.2.1 Filing an original of DHEC Form 0813, “Application for Radioactive Material License,” that includes the facility diagram, equipment, and training and experience qualifications of the Radiation Safety Officer, Associate Radiation Safety Officer(s), authorized user(s), authorized medical physicist(s), ophthalmic physicist(s), and authorized nuclear pharmacist(s); and

**Amend 4.7.3.1.2 to read:**

 4.7.3.1.2 A letter containing all information required by DHEC Form 0813; and

**Amend 4.7.4 to read:**

 4.7.4 In addition to the requirements in RHA 4.7.2 and 4.7.3 of this section an application for a license or amendment for medical use of radioactive material as described in RHA 4.88 must also include:

 4.7.4.1 Any additional aspects of the medical use of the material that are applicable to radiation safety that are not addressed in, or differ from, subparts A through C, L, and M of this part;

 4.7.4.2 Identification of and commitment to follow the applicable radiation safety program requirements in subparts D through H of this part that are appropriate for the specific RHA 4.88 medical use;

 4.7.4.3 Any additional specific information on ‑‑

 4.7.4.3.1 Radiation safety precautions and instructions;

 4.7.4.3.2 Methodology for measurement of dosages or doses to be administered to patients or human research subjects; and

 4.7.4.3.3 Calibration, maintenance, and repair of instruments and equipment necessary for radiation safety; and

 4.7.4.4 Any other information requested by the Department in its review of the application.

**Amend 4.8 to read:**

 A licensee shall apply for and must receive a license amendment—

 4.8.1 Before it receives, prepares, or uses radioactive material for a type of use that is permitted under this part, but that is not authorized on the licensee’s current license issued under this part;

 4.8.2 Before it permits anyone to work as an authorized user, authorized medical physicist, ophthalmic physicist, or authorized nuclear pharmacist under the license, except—

 4.8.2.1 For an authorized user, an individual who meets the requirements in RHA 4.24, 4.36.1, 4.39.1, 4.43.1, 4.44.1.1, 4.45.1.1, 4.54.1.1, 4.57.1.1, and 4.74.1.1;

 4.8.2.2 For an authorized nuclear pharmacist, an individual who meets the requirements in RHA 4.22.1 and RHA 4.24;

 4.8.2.3 For an authorized medical physicist, an individual who meets the requirements in RHA 4.21.1 and RHA 4.24;

 4.8.2.4 An individual who is identified as an authorized user, an authorized nuclear pharmacist, authorized medical physicist, or an ophthalmic physicist—

 4.8.2.4.1 On an NRC or Agreement State license or other equivalent permit or license recognized by the Department that authorizes the use of radioactive material in medical use or in the practice of nuclear pharmacy;

 4.8.2.4.2 On a license issued by an NRC or Agreement State specific license of broad scope that is authorized to permit the use of radioactive material in medical use or in the practice of nuclear pharmacy;

 4.8.2.4.3 On a license issued by an NRC master material licensee that is authorized to permit the use of radioactive material in medical use or in the practice of nuclear pharmacy; or

 4.8.2.4.4 By a commercial nuclear pharmacy that has been authorized to identify authorized nuclear pharmacists.

 4.8.3 Before it changes Radiation Safety Officers, except as provided in RHA 4.13.3;

 4.8.4 Before it permits anyone to work as an Associate Radiation Safety Officer, or before the Radiation Safety Officer assigns duties and tasks to an Associate Radiation Safety Officer that differ from those for which this individual is authorized on the license;

 4.8.5 Before it receives radioactive material in excess of the amount or in a different form, or receives a different radionuclide than is authorized on the license;

 4.8.6 Before it adds to or changes the areas of use identified in the application or on the license, except for areas of use where radioactive material is used only in accordance with either RHA 4.35 or 4.37;

 4.8.7 Before it changes the address(es) of use identified in the application or on the license;

 4.8.8 Before it revises procedures required by RHA 4.61, 4.67, 4.68 and 4.69, as applicable, where such revision reduces radiation safety; and

 4.8.9 Before it receives a sealed source from a different manufacturer or of a different model number than authorized by its license unless the sealed source is used for manual brachytherapy, is listed in the Sealed Source and Device Registry, and is in a quantity and for an isotope authorized by the license.

**Amend 4.9 to read:**

 4.9.1 A licensee shall provide the Department, no later than 30 days after the date that the licensee permits an individual to work under the provisions of RHA 4.8.2 as an authorized user, authorized medical physicist, ophthalmic physicist, or authorized nuclear pharmacist—

 4.9.1.1 A copy of the board certification and, as appropriate, verification of completion of:

 4.9.1.1.1 Training for the authorized medical physicist under RHA 2.21.4;

 4.9.1.1.2 Any additional case experience required in RHA 4.43.2.2.7 for an authorized user under RHA 4.40; or

 4.9.1.1.3 Device specific training in RHA 4.74.1.5 for the authorized user under RHA 4.58; or

 4.9.2 A copy of the Nuclear Regulatory Commission or Agreement State license, the permit issued by a Nuclear Regulatory Commission master material licensee, the permit issued by a Nuclear Regulatory Commission or Agreement State licensee of broad scope, the permit issued by a Nuclear Regulatory Commission master material license broad scope permittee, or documentation that only accelerator‑produced radioactive materials, discrete sources of radium‑226, or both, were used for medical use or in the practice of nuclear pharmacy at a Government agency or Federally recognized Indian Tribe before November 30, 2007, or at all other locations of use before August 8, 2009, or an earlier date as noticed by the Nuclear Regulatory Commission for each individual whom the licensee permits to work under the provisions of this section.

 4.9.2.1 A licensee shall notify the Department no later than 30 days after:

 4.9.2.1.1 An authorized user, an authorized nuclear pharmacist, a Radiation Safety Officer, an Associate Radiation Safety Officer, an authorized medical physicist, or ophthalmic physicist permanently discontinues performance of duties under the license or has a name change;

 4.9.2.1.2 The licensee permits an individual qualified to be a Radiation Safety Officer under RHA 4.20 and 4.24 to function as a temporary Radiation Safety Officer and to perform the functions of a Radiation Safety Officer in accordance with RHA 4.13.3;

 4.9.2.1.3 The licensee’s mailing address changes;

 4.9.2.1.4 The licensee’s name changes, but the name change does not constitute a transfer of control of the license as described in RHA 2.10.2.1 of this chapter;

 4.9.2.1.5 The licensee has added to or changed the areas of use identified in the application or on the license where radioactive material is used in accordance with either RHA 4.35 or RHA 4.37 if the change does not include addition or relocation of either an area where PET radionuclides are produced or a PET radioactive drug delivery line from the PET radionuclide/PET radioactive drug production area; or

 4.9.2.1.6 The licensee obtains a sealed source for use in manual brachytherapy from a different manufacturer or with a different model number than authorized by its license for which it did not require a license amendment as provided in RHA 4.8.9. The notification must include the manufacturer and model number of the sealed source, the isotope, and the quantity per sealed source.

 4.9.3 The licensee shall send the documents required in this section to the appropriate address identified in RHA 1.13.

**Amend 4.10.3 and 4.10.5 to read:**

 4.10.3 The provisions of RHA 4.8.6 regarding additions to or changes in the areas of use at the addresses identified in the application or on the license;

 4.10.5 The provisions of RHA 4.9.2.1.1 for an authorized user, an authorized nuclear pharmacist, authorized medical physicist, or an ophthalmic physicist;

**Amend 4.13.2 and 4.13.3 to read:**

 4.13.2 A licensee’s management shall appoint a Radiation Safety Officer, who agrees, in writing, to be responsible for implementing the radiation protection program. The licensee, through the Radiation Safety Officer, shall ensure that radiation safety activities are being performed in accordance with licensee‑approved procedures and regulatory requirements. A licensee’s management may appoint, in writing, one or more Associate Radiation Safety Officers to support the Radiation Safety Officer. The Radiation Safety Officer, with written agreement of the licensee’s management, must assign the specific duties and tasks to each Associate Radiation Safety Officer. These duties and tasks are restricted to the types of use for which the Associate Radiation Safety Officer is listed on a license. The Radiation Safety Officer may delegate duties and tasks to the Associate Radiation Safety Officer but shall not delegate the authority or responsibilities for implementing the radiation protection program.

 4.13.3 For up to 60 days each year, a licensee may permit an individual qualified to be a Radiation Safety Officer, under RHA 4.20 and 4.24, to function as a temporary Radiation Safety Officer and to perform the functions of a Radiation Safety Officer, as provided in RHA 4.13.7 of this section, if the licensee takes the actions required in RHA 4.13.2, 4.13.3, 4.13.7 and 4.13.8 of this section and notifies the Department in accordance with RHA 4.9.2.

**Amend 4.17.2.5 and 4.17.2.6 to read:**

 4.17.2.5 For high dose‑rate remote afterloading brachytherapy: the radionuclide, treatment site, dose per fraction, number of fractions, and total dose;

 4.17.2.6 For permanent implant brachytherapy:

 4.17.2.6.1 Before implantation: The treatment site, the radionuclide, and the total source strength; and

 4.17.2.6.2 After implantation but before the patient leaves the post‑treatment recovery area: The treatment site, the number of sources implanted, the total source strength implanted, and the date; or

 4.17.2.7 For all other brachytherapy, including low, medium, and pulsed dose rate remote afterloaders:

 4.17.2.7.1 Before implantation: The treatment site, radionuclide, and dose; and

 4.17.2.7.2 After implantation but before completion of the procedure: the radionuclide, treatment site, number of sources, and total source strength and exposure time (or the total dose), and date.

**Amend 4.18.2 to read:**

 4.18.2 At a minimum, the procedures required by RHA 4.18.1 must address the following items that are applicable to the licensee’s use of radioactive material—

 4.18.2.1 Verifying the identity of the patient or human research subject;

 4.18.2.2 Verifying that the administration is in accordance with the treatment plan, if applicable, and the written directive;

 4.18.2.3 Checking both manual and computer‑generated dose calculations;

 4.18.2.4 Verifying that any computer‑generated dose calculations are correctly transferred into the consoles of therapeutic medical units authorized by RHA 4.58 or RHA 4.88;

 4.18.2.5 Determining if a medical event, as defined in RHA 4.117, has occurred; and

 4.18.2.6 Determining, for permanent implant brachytherapy, within 60 calendar days from the date the implant was performed, the total source strength administered outside of the treatment site compared to the total source strength documented in the post‑implantation portion of the written directive, unless a written justification of patient unavailability is documented.

**Amend 4.20 to read:**

**RHA 4.20. Training for Radiation Safety Officers and Associate Radiation Safety Officer**

 Except as provided in RHA 4.23, the licensee shall require an individual fulfilling the responsibilities of the Radiation Safety Officer or an individual assigned duties and tasks as an Associate Radiation Safety Officer as provided in RHA 4.13 to be an individual who—

 4.20.1 Is certified by a specialty board whose certification process has been recognized by the Nuclear Regulatory Commission or an Agreement State and who meets the requirements in paragraphs 4.20.4 and 4.20.5 of this section. The names of board certifications that have been recognized by the Nuclear Regulatory Commission or an Agreement State are posted on the NRC’s Medical Uses Licensee Toolkit web page.

 4.20.1.1 To have its certification process recognized, a specialty board shall require all candidates for certification to:

 4.20.1.1.1 Hold a bachelor’s or graduate degree from an accredited college or university in physical science or engineering or biological science with a minimum of 20 college credits in physical science;

 4.20.1.1.2 Have 5 or more years of professional experience in health physics (graduate training may be substituted for no more than 2 years of the required experience) including at least 3 years in applied health physics; and

 4.20.1.1.3 Pass an examination administered by diplomats of the specialty board, which evaluates knowledge and competence in radiation physics and instrumentation, radiation protection, mathematics pertaining to the use and measurement of radioactivity, radiation biology, and radiation dosimetry; or

 4.20.1.2.1 Hold a master’s or doctor’s degree in physics, medical physics, other physical science, engineering, or applied mathematics from an accredited college or university;

 4.20.1.2.2 Have 2 years of full‑time practical training and/or supervised experience in medical physics:

 4.20.1.2.2.1 Under the supervision of a medical physicist who is certified in medical physics by a specialty board recognized by the Nuclear Regulatory Commission or an Agreement State; or

 4.20.1.2.2.2 In clinical nuclear medicine facilities providing diagnostic or therapeutic services under the direction of physicians who meet the requirements for authorized users in RHA 4.23, 4.39 or RHA 4.43; and

 4.20.1.2.3 Pass an examination, administered by diplomats of the specialty board, that assesses knowledge and competence in clinical diagnostic radiological or nuclear medicine physics and in radiation safety; or

 4.20.2 Has completed a structured educational program consisting of both:

 4.20.2.1 200 hours of classroom and laboratory training in the following areas—

 4.20.2.1.1 Radiation physics and instrumentation;

 4.20.2.1.2 Radiation protection;

 4.20.2.1.3 Mathematics pertaining to the use and measurement of radioactivity;

 4.20.2.1.4 Radiation biology; and

 4.20.2.1.5 Radiation dosimetry; and

 4.20.2.2 One year of full‑time radiation safety experience under the supervision of the individual identified as the Radiation Safety Office on Nuclear Regulatory Commission or Agreement State license or on a permit issued by an Nuclear Regulatory Commission master material licensee that authorizes similar type(s) of use(s) of radioactive material. An Associate Radiation Safety Officer may provide supervision for those areas for which the Associate Radiation Safety Officer is authorized on a Nuclear Regulatory Commission or an Agreement State license or permit issued by a Nuclear Regulatory Commission master material licensee. The full‑time radiation safety experience must involve the following—

 4.20.2.2.1 Shipping, receiving, and performing related radiation surveys;

 4.20.2.2.2 Using and performing checks for proper operation of instruments used to determine the activity of dosages, survey meters, and instruments used to measure radionuclides;

 4.20.2.2.3 Securing and controlling radioactive material;

 4.20.2.2.4 Using administrative controls to avoid mistakes in the administration of radioactive material;

 4.20.2.2.5 Using procedures to prevent or minimize radioactive contamination and using proper decontamination procedures;

 4.20.2.2.6 Using emergency procedures to control radioactive material; and

 4.20.2.2.7 Disposing of radioactive material; and

 4.20.2.3 This individual must obtain a written attestation, signed by a preceptor Radiation Safety Officer or Associate Radiation Safety Officer who has experience with the radiation safety aspects of similar types of use of radioactive material for which the individual is seeking approval as a Radiation Safety Officer or an Associate Radiation Safety Officer. The written attestation must state that the individual has satisfactorily completed the requirements in paragraphs RHA 4.20.2 and RHA 4.20.4 of this section, and is able to independently fulfill the radiation safety‑related duties as a Radiation Safety Officer or as an Associate Radiation Safety Officer for a medical use license; or

 4.20.3 Is a medical physicist who has been certified by a specialty board whose certification process has been recognized by the Nuclear Regulatory Commission or an Agreement State under RHA 4.21.1, has experience with the radiation safety aspects of similar types of use of radioactive material for which the licensee seeks the approval of the individual as Radiation Safety Officer or an Associate Radiation Safety Officer, and meets the requirements in paragraph 4.20.4 of this section; or

 4.20.3.1 Is an authorized user, authorized medical physicist, or authorized nuclear pharmacist identified on a Nuclear Regulatory Commission or an Agreement State license, a permit issued by a Nuclear Regulatory Commission master material licensee, a permit issued by a Nuclear Regulatory Commission or an Agreement State licensee of broad scope, or a permit issued by a Nuclear Regulatory Commission master material license broad scope permittee, has experience with the radiation safety aspects of similar types of use of radioactive material for which the licensee seeks the approval of the individual as the Radiation Safety Officer or Associate Radiation Safety Officer, and meets the requirements in paragraph 4.20.4 of this section; or

 4.20.3.2 Has experience with the radiation safety aspects of the types of use of radioactive material for which the individual is seeking simultaneous approval both as the Radiation Safety Officer and the authorized user on the same new medical use license or new medical use permit issued by a Nuclear Regulatory Commission master material license. The individual must also meet the requirements in paragraph 4.20.4 of this section.

 4.20.4 Has training in the radiation safety, regulatory issues, and emergency procedures for the types of use for which a licensee seeks approval. This training requirement may be satisfied by completing training that is supervised by a Radiation Safety Officer, an Associate Radiation Safety Officer, authorized medical physicist, authorized nuclear pharmacist, or authorized user, as appropriate, who is authorized for the type(s) of use for which the licensee is seeking approval.

**Amend 4.21 to read:**

 Except as provided in RHA 4.23, the licensee shall require the authorized medical physicist to be an individual who—

 4.21.1 Is certified by a specialty board whose certification process has been recognized by the Nuclear Regulatory Commission or an Agreement State and who meets the requirements in paragraph 4.21.4 of this section. The names of board certifications that have been recognized by the Nuclear Regulatory Commission or an Agreement State are posted on the NRC’s Medical Uses Licensee Toolkit web page. To have its certification process recognized, a specialty board shall require all candidates for certification to:

 4.21.1.1 Hold a master’s or doctor’s degree in physics, medical physics, other physical science, engineering, or applied mathematics from an accredited college or university.

 4.21.1.2 Have 2 years of full‑time practical training and/or supervised experience in medical physics—

 4.21.1.2.1 Under the supervision of a medical physicist who is certified in medical physics by a specialty board whose certification process has been recognized under this section by the Nuclear Regulatory Commission or an Agreement State; or

 4.21.1.2.2 In clinical radiation facilities providing high‑energy, external beam therapy (photons and electrons with energies greater than or equal to 1 million electron volts) and brachytherapy services under the direction of physicians who meet the requirements for authorized users in RHA 4.23, 4.54 or 4.74; and

 4.21.1.3 Pass an examination, administered by diplomats of the specialty board, that assesses knowledge and competence in clinical radiation therapy, radiation safety, calibration, quality assurance, and treatment planning for external beam therapy, brachytherapy, and stereotactic radiosurgery; or

 4.21.2 Holds a master’s or doctor’s degree in physics, medical physics, other physical science, engineering, or applied mathematics from an accredited college or university; and has completed 1 year of full‑time training in medical physics and an additional year of full‑time work experience under the supervision of an individual who meets the requirements for an authorized medical physicist for the type(s) of use for which the individual is seeking authorization. This training and work experience must be conducted in clinical radiation facilities that provide high‑energy, external beam therapy (photons and electrons with energies greater than or equal to 1 million electron volts) and brachytherapy services and must include:

 4.21.2.1 Performing sealed source leak tests and inventories;

 4.21.2.2 Performing decay corrections;

 4.21.2.3 Performing full calibration and periodic spot checks of external beam treatment units, stereotactic radiosurgery units, and remote afterloading units as applicable; and

 4.21.2.4 Conducting radiation surveys around external beam treatment units, stereotactic radiosurgery units, and remote afterloading units as applicable; and

 4.21.2.5 Has obtained written attestation that the individual has satisfactorily completed the requirements in RHA 4.21.2 and 4.21.3 of this section, and is able to independently fulfill the radiation safety‑related duties as an authorized medical physicist for each type of therapeutic medical unit for which the individual is requesting authorized medical physicist status. The written attestation must be signed by a preceptor authorized medical physicist who meets the requirements in RHA 4.21 or 4.23, or equivalent Nuclear Regulatory Commission or Agreement State requirements for an authorized medical physicist for each type of therapeutic medical unit for which the individual is requesting authorized medical physicist status.

 4.21.3 Has training for the type(s) of use for which authorization is sought that includes hands‑on device operation, safety procedures, clinical use, and the operation of a treatment planning system. This training requirement may be satisfied by satisfactorily completing either a training program provided by the vendor or by training supervised by an authorized medical physicist authorized for the type(s) of use for which the individual is seeking authorization.

**Amend 4.22.1 and 4.22.3 to read:**

 4.22.1 Is certified by a specialty board whose certification process has been recognized by the Nuclear Regulatory Commission or an Agreement State. The names of board certifications that have been recognized by the Nuclear Regulatory Commission or an Agreement State are posted on the NRC’s Medical Uses Licensee Toolkit webpage. To have its certification process recognized, a specialty board shall require all candidates for certification to:

 4.22.3 Has obtained written attestation signed by a preceptor authorized nuclear pharmacist, that the individual has satisfactorily completed the requirements in RHA 4.22.2 of this section and is able to independently fulfill the radiation safety‑related duties as an authorized nuclear pharmacist.

**Amend 4.23 to read:**

**RHA 4.23. Training for Experienced Radiation Safety Officer, Teletherapy or Medical Physicist, Authorized Medical Physicist, Authorized User, Nuclear Pharmacist, and Authorized Nuclear Pharmacist.**

 4.23.1 Training for Experienced Radiation Safety Officer, Teletherapy or Medical Physicist, and Nuclear Pharmacist.

 4.23.1.1 An individual identified on a Nuclear Regulatory Commission or an Agreement State license or a permit issued by a Nuclear Regulatory Commission or an Agreement State broad scope licensee or master material license permit or by a master material license permittee of broad scope as a Radiation Safety Officer, a teletherapy or medical physicist, an authorized medical physicist, a nuclear pharmacist or an authorized nuclear pharmacist on or before January 14, 2019, need not comply with the training requirements of RHA 4.20, RHA 4.21, or RHA 4.22, respectively, except the Radiation Safety Officers and authorized medical physicists identified in this paragraph must meet the training requirements in RHA 4.20.4 or RHA 4.21.3, as appropriate, for any material or uses for which they were not authorized prior to this date.

 4.23.1.2 Any individual certified by the American Board of Health Physics in Comprehensive Health Physics; American Board of Radiology; American Board of Nuclear Medicine; American Board of Science in Nuclear Medicine; Board of Pharmaceutical Specialties in Nuclear Pharmacy; American Board of Medical Physics in radiation oncology physics; Royal College of Physicians and Surgeons of Canada in nuclear medicine; American Osteopathic Board of Radiology; or American Osteopathic Board of Nuclear Medicine on or before October 24, 2005, need not comply with the training requirements of RHA 4.20 to be identified as a Radiation Safety Officer or as an Associate Radiation Safety Officer on a Nuclear Regulatory Commission or an Agreement State license or Nuclear Regulatory Commission master material license permit for those materials and uses that these individuals performed on or before October 24, 2005.

 4.23.1.3 Any individual certified by the American Board of Radiology in therapeutic radiological physics, Roentgen ray and gamma ray physics, x‑ray and radium physics, or radiological physics, or certified by the American Board of Medical Physics in radiation oncology physics, on or before October 24, 2005, need not comply with the training requirements for an authorized medical physicist described in RHA 4.21, for those materials and uses that these individuals performed on or before October 24, 2005.

 4.23.1.4 A Radiation Safety Officer, a medical physicist, or a nuclear pharmacist, who used only accelerator‑produced radioactive materials, discrete sources of radium‑226, or both, for medical uses or in the practice of nuclear pharmacy at a Government agency or Federally recognized Indian Tribe before November 30, 2007, or at all other locations of use before August 8, 2009, or an earlier date as noticed by the Nuclear Regulatory Commission, need not comply with the training requirements of RHA 4.20, RHA 4.21, or RHA 4.22, respectively, when performing the same uses. A nuclear pharmacist, who prepared only radioactive drugs containing accelerator‑produced radioactive materials, or a medical physicist, who used only accelerator‑produced radioactive materials, at the locations and during the time period identified in this paragraph, qualifies as an authorized nuclear pharmacist or an authorized medical physicist, respectively, for those materials and uses performed before these dates, for the purposes of this chapter.

 4.23.2 Training for Experienced Authorized User

 4.23.2.1 Physicians, dentists, or podiatrists identified as authorized users for the medical use of radioactive material on a license issued by the Nuclear Regulatory Commission or an Agreement State, a permit issued by a Nuclear Regulatory Commission master material licensee, a permit issued by a Nuclear Regulatory Commission or an Agreement State broad scope licensee, or a permit issued by a Nuclear Regulatory Commission master material license broad scope permittee on or before January 14, 2019, who perform only those medical uses for which they were authorized on or before that date need not comply with the training requirements of subparts D through H of this part.

 4.23.2.2 Physicians, dentists, or podiatrists not identified as authorized users for the medical use of radioactive material on a license issued by the Nuclear Regulatory Commission or an Agreement State, a permit issued by a Nuclear Regulatory Commission master material licensee, a permit issued by a Nuclear Regulatory Commission or an Agreement State broad scope licensee, or a permit issued by a Nuclear Regulatory Commission master material license of broad scope on or before October 24, 2005, need not comply with the training requirements of subparts D through H of this part for those materials and uses that these individuals performed on or before October 24, 2005, as follows:

 4.23.2.2.1 For uses authorized under RHA 4.35 or RHA 4.37, or oral administration of sodium iodide I–131 requiring a written directive for imaging and localization purposes, a physician who was certified on or before October 24, 2005, in nuclear medicine by the American Board of Nuclear Medicine; diagnostic radiology by the American Board of Radiology; diagnostic radiology or radiology by the American Osteopathic Board of Radiology; nuclear medicine by the Royal College of Physicians and Surgeons of Canada; or American Osteopathic Board of Nuclear Medicine in nuclear medicine;

 4.23.2.2.2 For uses authorized under RHA 4.40, a physician who was certified on or before October 24, 2005, by the American Board of Nuclear Medicine; the American Board of Radiology in radiology, therapeutic radiology, or radiation oncology; nuclear medicine by the Royal College of Physicians and Surgeons of Canada; or the American Osteopathic Board of Radiology after 1984;

 4.23.2.2.3 For uses authorized under RHA 4.46 or RHA 4.58, a physician who was certified on or before October 24, 2005, in radiology, therapeutic radiology or radiation oncology by the American Board of Radiology; radiation oncology by the American Osteopathic Board of Radiology; radiology, with specialization in radiotherapy, as a British "Fellow of the Faculty of Radiology" or "Fellow of the Royal College of Radiology"; or therapeutic radiology by the Canadian Royal College of Physicians and Surgeons; and

 4.23.2.2.4 For uses authorized under RHA 4.56, a physician who was certified on or before October 24, 2005, in radiology, diagnostic radiology, therapeutic radiology, or radiation oncology by the American Board of Radiology; nuclear medicine by the American Board of Nuclear Medicine; diagnostic radiology or radiology by the American Osteopathic Board of Radiology; or nuclear medicine by the Royal College of Physicians and Surgeons of Canada.

 4.23.2.3 Physicians, dentists, or podiatrists who used only accelerator‑produced radioactive materials, discrete sources of radium‑226, or both, for medical uses performed at a Government agency or Federally recognized Indian Tribe before November 30, 2007, or at all other locations of use before August 8, 2009, or an earlier date as noticed by the Nuclear Regulatory Commission, need not comply with the training requirements of subparts D through H of this part when performing the same medical uses. A physician, dentist, or podiatrist, who used only accelerator‑produced radioactive materials, discrete sources of radium‑226, or both, for medical uses at the locations and time period identified in this paragraph, qualifies as an authorized user for those materials and uses performed before these dates, for the purposes of this chapter.

**Amend 4.28 to read:**

 Any person authorized by RHA 4.6 for medical use of radioactive material may receive, possess, and use any of the following radioactive material for check, calibration, transmission, and reference use.

 4.28.1 Sealed sources, not exceeding 1.11 GBq (30 mCi) each, manufactured and distributed by a person licensed under RHA 2.7.7 of this chapter or equivalent NRC or Agreement State regulations.

 4.28.2 Sealed sources, not exceeding 1.11 GBq (30 mCi) each, redistributed by a licensee authorized to redistribute the sealed sources manufactured and distributed by a person licensed under RHA 2.7.7 of this chapter or equivalent Nuclear Regulatory Commission or Agreement State regulations, providing the redistributed sealed sources are in the original packaging and shielding and are accompanied by the manufacturer’s approved instructions.

 4.28.3 Any radioactive material with a half‑life not longer than 120 days in individual amounts not to exceed 0.56 GBq (15 mCi).

 4.28.4 Any radioactive material with a half‑life longer than 120 days in individual amounts not to exceed the smaller of 7.4 MBq (200 uCi) or 1000 times the quantities in Appendix C, RHA 3.54, of Part III of these regulations.

 4.28.5 Technetium‑99m in amounts as needed.

 4.28.6 Radioactive material in sealed sources authorized by this provision shall not be:

 4.28.6.1 Used for medical use as defined in RHA 4.2 except in accordance with the requirements in RHA 4.56 or

 4.28.6.2 Combined (i.e., bundled or aggregated) to create an activity greater than the maximum activity of any single sealed source authorized under this section.

 4.28.6.3 A licensee using calibration, transmission, and reference sources in accordance with the requirements in this section need not list these sources on a specific medical use license.

**Amend the title of 4.35 to read:**

**RHA 4.35. Use of Unsealed Radioactive Material for Uptake, Dilution, and Excretion Studies for Which a Written Directive is not Required.**

**Amend 4.36 to read:**

 Except as provided in RHA 4.23, the licensee shall require an authorized user of unsealed radioactive material for the uses authorized under RHA 4.35 to be a physician who—

 4.36.1 Is certified by a medical specialty board whose certification process has been recognized by the Nuclear Regulatory Commission or an Agreement State. The names of board certifications that have been recognized by the NRC or an Agreement State are posted on the NRC’s Medical Uses Licensee Toolkit web page. To have its certification process recognized, a specialty board shall require all candidates for certification to:

 4.36.1.1 Complete 60 hours of training and experience in basic radionuclide handling techniques and radiation safety applicable to the medical use of unsealed radioactive material for uptake, dilution, and excretion studies that includes the topics listed in paragraphs 4.36.3 through 4.36.3.2.6 of this section; and

4.36.1.2 Pass an examination, administered by diplomats of the specialty board, that assesses knowledge and competence in radiation safety, radionuclide handling, and quality control; or

 4.36.2 Is an authorized user under RHA 4.39 or 4.43 or equivalent NRC requirements; or 4.36.3—

 4.36.3 Has completed 60 hours of training and experience, including a minimum of 8 hours of classroom and laboratory training, in basic radionuclide handling techniques applicable to the medical use of unsealed radioactive material for uptake, dilution, and excretion studies. The training and experience must include—

 4.36.3.1 Classroom and laboratory training in the following areas—

 4.36.3.1.1 Radiation physics and instrumentation;

 4.36.3.1.2 Radiation protection;

 4.36.3.1.3 Mathematics pertaining to the use and measurement of radioactivity;

 4.36.3.1.4 Chemistry of radioactive material for medical use; and

 4.36.3.1.5 Radiation biology; and

 4.36.3.2 Work experience, under the supervision of an authorized user who meets the requirements in RHA 4.23, 4.36, 4.39 or 4.43 or equivalent NRC requirements, involving—

 4.36.3.2.1 Ordering, receiving, and unpacking radioactive materials safely and performing the related radiation surveys;

 4.36.3.2.2 Performing quality control procedures on instruments used to determine the activity of dosages and performing checks for proper operation of survey meters;

 4.36.3.2.3 Calculating, measuring, and safely preparing patient or human research subject dosages;

 4.36.3.2.4 Using administrative controls to prevent a medical event involving the use of unsealed radioactive material;

 4.36.3.2.5 Using procedures to contain spilled radioactive material safely and using proper decontamination procedures; and

 4.36.3.2.6 Administering dosages of radioactive drugs to patients or human research subjects; and

 4.36.3.3 Has obtained written attestation that the individual has satisfactorily completed the requirements in paragraph 4.36.3 of this section and is able to independently fulfill the radiation safety‑related duties as an authorized user for the medical uses authorized under 4.35. The attestation must be obtained from either:

 4.36.3.3.1 A preceptor authorized user who meets the requirements in RHA 4.23, 4.36, 4.39, or 4.43, or equivalent Agreement State requirements; or

 4.36.3.3.2 A residency program director who affirms in writing that the attestation represents the consensus of the residency program faculty where at least one faculty member is an authorized user who meets the requirements in RHA 4.23, 4.36, 4.39, or 4.43, or equivalent Agreement State requirements, and concurs with the attestation provided by the residency program director. The residency training program must be approved by the Residency Review Committee of the Accreditation Council for Graduate Medical Education or the Royal College of Physicians and Surgeons of Canada or the Council on Postdoctoral Training of the American Osteopathic Association and must include training and experience specified in paragraph 4.36.3 of this section.

**Amend 4.38 to read:**

**RHA 4.38. Permissible Molybdenum‑99, Strontium‑82, and Strontium‑85 Concentrations.**

 4.38.1 A licensee may not administer to humans a radiopharmaceutical that contains:

 4.38.1.1 More than 0.15 kilobecquerel of molybdenum‑99 per megabecquerel of technetium‑99m (0.15 microcurie of molybdenum‑99 per millicurie of technetium‑99m); or

 4.38.1.2 More than 0.02 kilobecquerel of strontium‑82 per megabecquerel of rubidium‑82 chloride injection (0.02 microcurie of strontium‑82 per millicurie of rubidium‑82 chloride); or more than 0.2 kilobecquerel of strontium‑85 per megabecquerel of rubidium‑82 chloride injection (0.2 microcurie of strontium‑85 per millicurie of rubidium‑82).

 4.38.2 A licensee that uses molybdenum‑99/technetium‑99m generators for preparing a technetium‑99m radiopharmaceutical shall measure the molybdenum‑99 concentration in each eluate from a generator to demonstrate compliance with RHA 4.38.1.

 4.38.3 A licensee that uses a strontium‑82/rubidium‑82 generator for preparing a rubidium‑82 radiopharmaceutical shall, before the first patient use of the day, measure the concentration of radionuclides strontium‑82 and strontium‑85 to demonstrate compliance with RHA 4.38.1.

 4.38.4 If a licensee is required to measure the molybdenum‑99 concentration, the licensee shall retain a record of each measurement in accordance with RHA 4.101.

 4.38.5 The licensee shall report any measurement that exceeds the limits in RHA 4.38.1 of this section at the time of generator elution, in accordance with RHA 4.120.

**Amend 4.39 to read:**

 Except as provided in RHA 4.23, the licensee shall require an authorized user of unsealed radioactive material for the uses authorized under RHA 4.37 to be a physician who—

 4.39.1 Is certified by a medical specialty board whose certification process has been recognized by the Nuclear Regulatory Commission or an Agreement State. The names of board certifications that have been recognized by the Nuclear Regulatory Commission or an Agreement State are posted on the NRC’s Medical Uses Licensee Toolkit Web page. To have its certification process recognized, a specialty board shall require all candidates for certification to:

 4.39.1.1 Complete 700 hours of training and experience in basic radionuclide handling techniques and radiation safety applicable to the medical use of unsealed radioactive material for imaging and localization studies that includes the topics listed in paragraphs RHA 4.39.3 through 4.39.3.2.7; and

 4.39.1.2 Pass an examination, administered by diplomats of the specialty board, which assesses knowledge and competence in radiation safety, radionuclide handling, and quality control; or

 4.39.2 Is an authorized user under RHA 4.43 and meets the requirements in RHA 4.39.3.2.7 or equivalent NRC requirements; or

 4.39.3 Has completed 700 hours of training and experience, including a minimum of 80 hours of classroom and laboratory training, in basic radionuclide handling techniques applicable to the medical use of unsealed radioactive material for imaging and localization studies. The training and experience must include, at a minimum,‑

 4.39.3.1 Classroom and laboratory training in the following areas—

 4.39.3.1.1 Radiation physics and instrumentation;

 4.39.3.1.2 Radiation protection;

 4.39.3.1.3 Mathematics pertaining to the use and measurement of radioactivity;

 4.39.3.1.4 Chemistry of radioactive material for medical use;

 4.39.3.1.5 Radiation biology; and

 4.39.3.2 Work experience, under the supervision of an authorized user who meets the requirements in RHA 4.23, 4.39 or 4.43 and 4.39.3.2.7 or equivalent NRC or Agreement State requirements. An authorized nuclear pharmacist who meets the requirements in RHA 4.22 or RHA 4.23 may provide the supervised work experience for paragraph 4.39.3.2.7 of this section. Work experience must involve—

 4.39.3.2.1 Ordering, receiving, and unpacking radioactive materials safely and performing the related radiation surveys;

 4.39.3.2.2 Performing quality control procedures on instruments used to determine the activity of dosages and performing checks for proper operation of survey meters;

 4.39.3.2.3 Calculating, measuring, and safely preparing patient or human research subject dosages;

 4.39.3.2.4 Using administrative controls to prevent a medical event involving the use of unsealed radioactive material;

 4.39.3.2.5 Using procedures to safely contain spilled radioactive material and using proper decontamination procedures;

 4.39.3.2.6 Administering dosages of radioactive drugs to patients or human research subjects; and

 4.39.3.2.7 Eluting generator systems appropriate for preparation of radioactive drugs for imaging and localization studies, measuring and testing the eluate for radionuclidic purity, and processing the eluate with reagent kits to prepare labeled radioactive drugs; and

 4.39.3.3 Has obtained written attestation that the individual has satisfactorily completed the requirements in paragraph 4.39.3 of this section and is able to independently fulfill the radiation safety‑related duties as an authorized user for the medical uses authorized under RHA 4.35 and 4.37. The attestation must be obtained from either:

 4.39.3.3.1 A preceptor authorized user who meets the requirements in RHA 4.23, RHA 4.39, or RHA 4.43 and RHA 4.39.3.2.7, or equivalent Nuclear Regulatory Commission or Agreement State requirements; or

 4.39.3.3.2 A residency program director who affirms in writing that the attestation represents the consensus of the residency program faculty where at least one faculty member is an authorized user who meets the requirements in RHA 4.23, RHA 4.39, or RHA 4.43 and RHA 4.39.3.2.7, or equivalent Nuclear Regulatory Commission or Agreement State requirements, and concurs with the attestation provided by the residency program director. The residency training program must be approved by the Residency Review Committee of the Accreditation Council for Graduate Medical Education or the Royal College of Physicians and Surgeons of Canada or the Council on Postdoctoral Training of the American Osteopathic Association and must include training and experience specified in paragraph 4.39.3 of this section.

**Amend the title of Subpart E to read:**

***SUBPART E***

***Unsealed Radioactive Material–Written Directive Required***

**Amend the title and introductory paragraph of 4.40 to read:**

**RHA 4.40. Use of Unsealed Radioactive Material for Which a Written Directive is Required.**

 A licensee may use any unsealed radioactive material identified in RHA 4.43.2.2.7 prepared for medical use and for which a written directive is required that is—

**Amend 4.43 to read:**

 Except as provided in RHA 4.23, the licensee shall require an authorized user of unsealed radioactive material for the uses authorized under RHA 4.40 to be a physician who—

 4.43.1 Is certified by a medical specialty board whose certification process has been recognized by the Nuclear Regulatory Commission or an Agreement State and who meets the requirements in paragraphs 4.43.2.2.7 of this section. The names of board certifications that have been recognized by the Nuclear Regulatory Commission or an Agreement State are posted on the NRC’s Medical Uses Licensee Toolkit Web page. To be recognized, a specialty board shall require all candidates for certification to:

 4.43.1.1 Successfully complete residency training in a radiation therapy or nuclear medicine training program or a program in a related medical specialty. These residency training programs must include 700 hours of training and experience as described in paragraphs 4.43.2.1 through 4.43.2.2.5 of this section. Eligible training programs must be approved by the Residency Review Committee of the Accreditation Council for Graduate Medical Education, the Royal College of Physicians and Surgeons of Canada, or the Committee on Post‑Graduate Training of the American Osteopathic Association; and

 4.43.1.2 Pass an examination, administered by diplomats of the specialty board, which tests knowledge and competence in radiation safety, radionuclide handling, quality assurance, and clinical use of unsealed radioactive material for which a written directive is required; or

 4.43.2 Has completed 700 hours of training and experience, including a minimum of 200 hours of classroom and laboratory training, in basic radionuclide handling techniques applicable to the medical use of unsealed radioactive material requiring a written directive. The training and experience must include—

 4.43.2.1 Classroom and laboratory training in the following areas—

 4.43.2.1.1 Radiation physics and instrumentation;

 4.43.2.1.2 Radiation protection;

 4.43.2.1.3 Mathematics pertaining to the use and measurement of radioactivity;

 4.43.2.1.4 Chemistry of radioactive material for medical use; and

 4.43.2.1.5 Radiation biology; and

 4.43.2.2 Work experience, under the supervision of an authorized user who meets the requirements in RHA 4.23, 4.43, or equivalent NRC requirements. A supervising authorized user, who meets the requirements in RHA 4.43.2, must also have experience in administering dosages in the same dosage category or categories (i.e., RHA 4.43.2.2.7) as the individual requesting authorized user status. The work experience must involve—

 4.43.2.2.1 Ordering, receiving, and unpacking radioactive materials safely and performing the related radiation surveys;

 4.43.2.2.2 Performing quality control procedures on instruments used to determine the activity of dosages, and performing checks for proper operation of survey meters;

 4.43.2.2.3 Calculating, measuring, and safely preparing patient or human research subject dosages;

 4.43.2.2.4 Using administrative controls to prevent a medical event involving the use of unsealed radioactive material;

 4.43.2.2.5 Using procedures to contain spilled radioactive material safely and using proper decontamination procedures;

 4.43.2.2.6 [Reserved]

 4.43.2.2.7 Administering dosages of radioactive drugs to patients or research subjects from the three categories in this paragraph. Radioactive drugs containing radionuclides in categories not included in this paragraph are regulated under RHA 4.88. This work experience must involve a minimum of three cases in each of the following categories for which the individual is requesting authorized user status‑‑

 4.43.2.2.7.1 Oral administration of less than or equal to 1.22 gigabecquerels (33 millicuries) of sodium iodide I‑131, for which a written directive is required;

 4.43.2.2.7.2 Oral administration of greater than 1.22 gigabecquerels (33 millicuries) of sodium iodide I‑131;2

 4.43.2.2.7.3 Parenteral administration of any radioactive drug that contains a radionuclide that is primarily used for its electron emission, beta radiation characteristics, alpha radiation characteristics, or photon energy of less than 150 keV, for which a written directive is required; and

 4.43.2.3 Has obtained written attestation that the individual has satisfactorily completed the requirements in paragraph 4.43.2 of this section and is able to independently fulfill the radiation safety‑related duties as an authorized user for the medical uses authorized under RHA 4.40 for which the individual is requesting authorized user status. The attestation must be obtained from either:

 4.43.2.3.1 A preceptor authorized user who meets the requirements in 4.23, 4.43, or equivalent Nuclear Regulatory Commission or Agreement State requirements and has experience in administering dosages in the same dosage category or categories as the individual requesting authorized user status; or

 4.43.2.3.2 A residency program director who affirms in writing that the attestation represents the consensus of the residency program faculty where at least one faculty member is an authorized user who meets the requirements in 4.23, 4.43, or equivalent Nuclear Regulatory Commission or Agreement State requirements, has experience in administering dosages in the same dosage category or categories as the individual requesting authorized user status, and concurs with the attestation provided by the residency program director. The residency training program must be approved by the Residency Review Committee of the Accreditation Council for Graduate Medical Education or the Royal College of Physicians and Surgeons of Canada or the Council on Postdoctoral Training of the American Osteopathic Association and must include training and experience specified in paragraph 4.43.2 of this section.

 4.43.3 Training for the parenteral administration of unsealed byproduct material requiring a written directive.

 4.43.3.1 Except as provided in RHA 4.23, the licensee shall require an authorized user for the parenteral administration requiring a written directive, to be a physician who—

 4.43.3.1.1 Is an authorized user under RHA 4.43 uses listed in RHA 4.43.2.2.7.3 or equivalent NRC or Agreement State requirements; or

 4.43.3.1.2 Is an authorized user under RHA 4.54, 4.74, or equivalent NRC or Agreement State requirements and who meets the requirements in RHA 4.43.3.2 of this section; or

 4.43.3.1.3 Is certified by a medical specialty board whose certification process has been recognized by the NRC or an Agreement State under RHA 4.54 or 4.74, and who meets the requirements in RHA 4.43.3.2 of this section.

 4.43.3.2 The Physician‑‑

 4.43.3.2.1 Has successfully completed 80 hours of classroom and laboratory training, applicable to parenteral administrations, listed in RHA 4.43.2.2.7.3. The training must include—

 4.43.3.2.1.1 Radiation physics and instrumentation;

 4.43.3.2.1.2 Radiation protection;

 4.43.3.2.1.3 Mathematics pertaining to the use and measurement of radioactivity;

 4.43.3.2.1.4 Chemistry of radioactive material for medical use; and

 4.43.3.2.1.5 Radiation biology; and

 4.43.3.2.2 Has work experience, under the supervision of an authorized user who meets the requirements in RHA 4.23, 4.43, 4.43.3 or equivalent NRC or Agreement State requirements, in the parenteral administration listed in RHA 4.43.2.2.7.3. A supervising authorized user who meets the requirements in RHA 4.43, 4.43.3, or equivalent Nuclear Regulatory Commission or Agreement State requirements must have experience in administering dosages in the same category or categories as the individual requesting authorized user status. The work experience must involve—

 4.43.3.2.2.1 Ordering, receiving, and unpacking radioactive materials safely, and performing the related radiation surveys;

 4.43.3.2.2.2 Performing quality control procedures on instruments used to determine the activity of dosages, an performing checks for proper operation of survey meters;

 4.43.3.2.2.3 Calculating, measuring, and safely preparing patient or human research subject dosages;

 4.43.3.2.2.4 Using administrative controls to prevent a medical event involving the use of unsealed radioactive material;

 4.43.3.2.2.5 Using procedures to contain spilled radioactive material safely, and using proper decontamination procedures; and

 4.43.3.2.2.6 Administering dosages to patients or human research subjects, that include at least three cases of parenteral administrations as specified in RHA 4.43.2.2.7.3; and

 4.43.3.3 Has obtained written attestation that the individual has satisfactorily completed the requirements in paragraphs 4.43.3.2.1 and 4.43.3.2.2 of this section, and is able to independently fulfill the radiation safety‑related duties as an authorized user for the parenteral administration of unsealed radioactive material requiring a written directive. The attestation must be obtained from either:

 4.43.3.3.1 A preceptor authorized user who meets the requirements in RHA 4.23, RHA 4.43, RHA 4.43.3, or equivalent Nuclear Regulatory Commission or Agreement State requirements. A preceptor authorized user who meets the requirements in RHA 4.43, RHA 4.43.3, or equivalent Nuclear Regulatory Commission or Agreement State requirements, must have experience in administering dosages in the same category or categories as the individual requesting authorized user status; or

 4.43.3.3.2 A residency program director who affirms in writing that the attestation represents the consensus of the residency program faculty where at least one faculty member is an authorized user who meets the requirements in RHA 4.23, RHA 4.43, RHA 4.43.3, or equivalent Nuclear Regulatory Commission or Agreement State requirements, has experience in administering dosages in the same dosage category or categories as the individual requesting authorized user status, and concurs with the attestation provided by the residency program director. The residency training program must be approved by the Residency Review Committee of the Accreditation Council for Graduate Medical Education or the Royal College of Physicians and Surgeons of Canada or the Council on Postdoctoral Training of the American Osteopathic Association and must include training and experience specified in paragraphs 4.43.3.2.1 and 4.43.3.2.2 of this section.

2Experience with at least three cases in RHA 4.43.2.2.7.2 also satisfies the requirement in RHA 4.43.2.2.7.1.

**Amend 4.44 to read:**

Except as provided in RHA 4.23, the licensee shall require an authorized user for the oral administration of sodium iodide I‑131 requiring a written directive in quantities less than or equal to 1.22 Gigabecquerels (33 millicuries), to be a physician who—

 4.44.1 Is certified by a medical specialty board whose certification process includes all of the requirements in paragraphs 4.44.1.3 and 4.44.1.4 of this section and whose certification process has been recognized by the Nuclear Regulatory Commission or an Agreement State. The names of board certifications that have been recognized by the Nuclear Regulatory Commission or an Agreement State are posted on the NRC’s Medical Uses Licensee Toolkit Web page; or

 4.44.2 Is an authorized user under RHA 4.43, for uses listed in RHA 4.43.2.2.7.1 or 4.43.2.2.7.2, RHA 4.45, or equivalent NRC requirements; or

 4.44.3 Has successfully completed 80 hours of classroom and laboratory training, applicable to the medical use of sodium iodide I‑131 for procedures requiring a written directive. The training must include—

 4.44.3.1 Radiation physics and instrumentation;

 4.44.3.2 Radiation protection;

 4.44.3.3 Mathematics pertaining to the use and measurement of radioactivity;

 4.44.3.4 Chemistry of radioactive material for medical use; and

 4.44.3.5 Radiation biology; and

 4.44.3.6 Has work experience, under the supervision of an authorized user who meets the requirements in RHA 4.23, 4.43, RHA 4.44, RHA 4.45, or equivalent NRC requirements. A supervising authorized user who meets the requirements in RHA 4.43.2 must have experience in administering dosages as specified in RHA 4.43.2.2.7.1 or 4.43.2.2.7.2. The work experience must involve—

 4.44.3.6.1 Ordering, receiving, and unpacking radioactive materials safely and performing the related radiation surveys;

 4.44.3.6.2 Performing quality control procedures on instruments used to determine the activity of dosages and performing checks for proper operation for survey meters;

 4.44.3.6.3 Calculating, measuring, and safely preparing patient or human research subject dosages;

 4.44.3.6.4 Using administrative controls to prevent a medical event involving the use of radioactive material;

 4.44.3.6.5 Using procedures to contain spilled radioactive material safely and using proper decontamination procedures; and

 4.44.3.6.6 Administering dosages to patients or human research subjects, that includes at least 3 cases involving the oral administration of less than or equal to 1.22 Gigabecquerels (33 millicuries) of sodium iodide I‑131; and

 4.44.3.7 Has obtained written attestation that the individual has satisfactorily completed the requirements in paragraphs 4.44.3 of this section, and is able to independently fulfill the radiation safety‑related duties as an authorized user for oral administration of less than or equal to 1.22 gigabecquerels (33 millicuries) of sodium iodide I–131 for medical uses authorized under RHA 4.40. The attestation must be obtained from either:

 4.44.3.7.1 A preceptor authorized user who meets the requirements in RHA 4.23, RHA 4.43, RHA 4.44, RHA 4.45, or equivalent Nuclear Regulatory Commission or Agreement State requirements and has experience in administering dosages as specified in RHA 4.43.2.2.7.1 or RHA 4.43.2.2.7.2; or

 4.44.3.7.2 A residency program director who affirms in writing that the attestation represents the consensus of the residency program faculty where at least one faculty member is an authorized user who meets the requirements in RHA 4.23, RHA 4.43, RHA 4.44, RHA 4.45, or equivalent Agreement State requirements, has experience in administering dosages as specified in RHA 4.43.2.2.7.1 or RHA 4.43.2.2.7.2, and concurs with the attestation provided by the residency program director. The residency training program must be approved by the Residency Review Committee of the Accreditation Council for Graduate Medical Education or the Royal College of Physicians and Surgeons of Canada or the Council on Postdoctoral Training of the American Osteopathic Association and must include training and experience specified in paragraphs 4.44.1.3 and 4.44.1.4 of this section.

**Amend 4.45 to read:**

Except as provided in RHA 4.23, the licensee shall require an authorized user for the oral administration of sodium iodide I‑131 requiring a written directive in quantities greater than 1.22 Gigabecquerels (33 millicuries), to be a physician who—

 4.45.1 Is certified by a medical specialty board whose certification process includes all of the requirements in paragraphs 4.45.1.3 and 4.45.1.4 of this section, and whose certification has been recognized by the Nuclear Regulatory Commission or an Agreement State. The names of board certifications that have been recognized by the Nuclear Regulatory Commission or an Agreement State are posted on the NRC’s Medical Uses Licensee Toolkit Web page; or

 4.45.2 Is an authorized user under RHA 4.43.1, 4.43.2 for uses listed in RHA 4.43.2.2.7.2, or equivalent NRC requirements; or

 4.45.3 Has successfully completed 80 hours of classroom and laboratory training, applicable to the medical use of sodium iodide I‑131 for procedures requiring a written directive. The training must include—

 4.45.3.1 Radiation physics and instrumentation;

 4.45.3.2 Radiation protection;

 4.45.3.3 Mathematics pertaining to the use and measurement of radioactivity;

 4.45.3.4 Chemistry of radioactive material for medical use; and

 4.45.3.5 Radiation biology; and

 4.45.3.6 Has work experience, under the supervision of an authorized user who meets the requirements in RHA 4.23, 4.43, 4.45, or equivalent NRC requirements. A supervising authorized user, who meets the requirements in RHA 4.43.2, must also have experience in administering dosages as specified in RHA 4.43.2.2.7.2. The work experience must involve—

 4.45.3.6.1 Ordering, receiving, and unpacking radioactive materials safely and performing the related radiation surveys;

 4.45.3.6.2 Performing quality control procedures on instruments used to determine the activity of dosages and performing checks for proper operation for survey meters;

 4.45.3.6.3 Calculating, measuring, and safely preparing patient or human research subject dosages;

 4.45.3.6.4 Using administrative controls to prevent a medical event involving the use of radioactive material;

 4.45.3.6.5 Using procedures to contain spilled radioactive material safely and using proper decontamination procedures; and

 4.45.3.6.6 Administering dosages to patients or human research subjects, that includes at least 3 cases involving the oral administration of greater than 1.22 Gigabecquerels (33 millicuries) of sodium iodide I‑131; and

 4.45.3.7 Has obtained written attestation that the individual has satisfactorily completed the requirements in paragraphs 4.45.3 of this section, and is able to independently fulfill the radiation safety‑related duties as an authorized user for oral administration of greater than or equal to 1.22 gigabecquerels (33 millicuries) of sodium iodide I–131 for medical uses authorized under RHA 4.40. The attestation must be obtained from either:

 4.45.3.7.1 A preceptor authorized user who meets the requirements in RHA 4.23, 4.43, 4.45, or equivalent Nuclear Regulatory Commission or Agreement State requirements and has experience in administering dosages as specified in 4.43.2.2.7.2; or

 4.45.3.7.2 A residency program director who affirms in writing that the attestation represents the consensus of the residency program faculty where at least one faculty member is an authorized user who meets the requirements in RHA 4.23, 4.43, 4.45, or equivalent Nuclear Regulatory Commission or Agreement State requirements, has experience in administering dosages as specified in 4.43.2.2.7.2, and concurs with the attestation provided by the residency program director. The residency training program must be approved by the Residency Review Committee of the Accreditation Council for Graduate Medical Education or the Royal College of Physicians and Surgeons of Canada or the Council on Postdoctoral Training of the American Osteopathic Association and must include training and experience specified in paragraphs 4.45.3 of this section.

**Amend 4.46 to read:**

 4.46.1 A licensee must use only brachytherapy sources:

 4.46.1.1 Approved in the Sealed Source and Device Registry for manual brachytherapy medical use. The manual brachytherapy sources may be used for manual brachytherapy uses that are not explicitly listed in the Sealed Source and Device Registry, but must be used in accordance with the radiation safety conditions and limitations described in the Sealed Source and Device Registry; or

 4.46.1.2 In research to deliver therapeutic doses for medical use in accordance with an active Investigational Device Exemption (IDE) application accepted by the U.S. Food and Drug Administration provided the requirements of RHA 4.19.1 are met.

**Amend 4.52 to read:**

**RHA 4.52. Strontium‑90 Sources for Ophthalmic Treatments.**

 4.52.1 Licensees who use strontium‑90 for ophthalmic treatments must ensure that certain activities as specified in 4.52.2 of this section are performed by either:

 4.52.1.1 An authorized medical physicist; or

 4.52.1.2 An individual who:

 4.52.1.2.1 Is identified as an ophthalmic physicist on a specific medical use license issued by the Nuclear Regulatory Commission or an Agreement State; permit issued by a Nuclear Regulatory Commission or Agreement State broad scope medical use licensee; medical use permit issued by a Nuclear Regulatory Commission master material licensee; or permit issued by a Nuclear Regulatory Commission master material licensee broad scope medical use permittee; and

 4.52.1.2.2 Holds a master’s or doctor’s degree in physics, medical physics, other physical sciences, engineering, or applied mathematics from an accredited college or university; and

 4.52.1.2.3 Has successfully completed 1 year of full‑time training in medical physics and an additional year of full‑time work experience under the supervision of a medical physicist; and

 4.52.1.2.4 Has documented training in:

 4.52.1.2.4.1 The creation, modification, and completion of written directives;

 4.52.1.2.4.2 Procedures for administrations requiring a written directive; and

 4.52.1.2.4.3 Performing the calibration measurements of brachytherapy sources as detailed in RHA 4.51.

 4.52.2 The individuals who are identified in 4.52.1 of this section must:

 4.52.2.1 Calculate the activity of each strontium‑90 source that is used to determine the treatment times for ophthalmic treatments. The decay must be based on the activity determined under RHA 4.51; and

 4.52.2.2 Assist the licensee in developing, implementing, and maintaining written procedures to provide high confidence that the administration is in accordance with the written directive. These procedures must include the frequencies that the individual meeting the requirements in 4.52.1 of this section will observe treatments, review the treatment methodology, calculate treatment time for the prescribed dose, and review records to verify that the administrations were in accordance with the written directives.

 4.52.3 Licensees must retain a record of the activity of each strontium‑90 source in accordance with RHA 4.106.

**Amend 4.54 to read:**

Except as provided in RHA 4.23, the licensee shall require an authorized user of a manual brachytherapy source for the uses authorized under RHA 4.46 to be a physician who—

 4.54.1 Is certified by a medical specialty board whose certification process has been recognized by the Nuclear Regulatory Commission or an Agreement State. The names of board certifications that have been recognized by the Nuclear Regulatory Commission or an Agreement State are posted on the NRC’s Medical Uses Licensee Toolkit Web page. To have its certification process recognized, a specialty board shall require all candidates for certification to:

 4.54.1.1 Successfully complete a minimum of 3 years of residency training in a radiation oncology program approved by the Residency Review committee of the Accreditation Council for Graduate Medical Education or the Royal College of Physicians and Surgeons of Canada or the Committee on Post‑Graduate Training of the American Osteopathic Association; and

 4.54.1.2 Pass an examination, administered by diplomats of the specialty board, that tests knowledge and competence in radiation safety, radionuclide handling, treatment planning, quality assurance, and clinical use of manual brachytherapy; or

 4.54.2 Has completed a structured educational program in basic radionuclide handling techniques applicable to the use of manual brachytherapy sources that includes—

 4.54.2.1 200 hours of classroom and laboratory training in the following areas:

 4.54.2.1.1 Radiation physics and instrumentation;

 4.54.2.1.2 Radiation protection;

 4.54.2.1.3 Mathematics pertaining to the use and measurement of radioactivity; and

 4.54.2.1.4 Radiation biology; and

 4.54.2.2 500 hours of work experience, under the supervision of an authorized user who meets the requirements in RHA 4.23, 4.54, or equivalent NRC or Agreement State requirements at a medical facility authorized to use radioactive material under RHA 4.46, involving—

 4.54.2.2.1 Ordering, receiving, and unpacking radioactive materials safely and performing the related radiation surveys;

 4.54.2.2.2 Checking survey meters for proper operation;

 4.54.2.2.3 Preparing, implanting, and removing brachytherapy sources;

 4.54.2.2.4 Maintaining running inventories of material on hand;

 4.54.2.2.5 Using administrative controls to prevent a medical event involving the use of radioactive material;

 4.54.2.2.6 Using emergency procedures to control radioactive material; and

 4.54.2.3 Has completed 3 years of supervised clinical experience in radiation oncology, under an authorized user who meets the requirements in RHA 4.23, 4.54 or equivalent NRC requirements, as part of a formal training program approved by the Residency Review Committee for Radiation Oncology of the Accreditation Council for Graduate Medical Education or the Royal College of Physicians and Surgeons of Canada or the Committee on Postdoctoral Training of the American Osteopathic Association. This experience may be obtained concurrently with the supervised work experience required by RHA 4.54.2.2; and

 4.54.2.4 Has obtained written attestation that the individual has satisfactorily completed the requirements in paragraphs 4.54.2.1 and 4.54.2.2 of this section and is able to independently fulfill the radiation safety‑related duties as an authorized user of manual brachytherapy sources for the medical uses authorized under RHA 4.46. The attestation must be obtained from either:

 4.54.2.4.1 A preceptor authorized user who meets the requirements in RHA 4.23, RHA 4.54, or equivalent Nuclear Regulatory Commission or Agreement State requirements; or

 4.54.2.4.2 A residency program director who affirms in writing that the attestation represents the consensus of the residency program faculty where at least one faculty member is an authorized user who meets the requirements in RHA 4.23, RHA 4.54, or equivalent Agreement State requirements, and concurs with the attestation provided by the residency program director. The residency training program must be approved by the Residency Review Committee of the Accreditation Council for Graduate Medical Education or the Royal College of Physicians and Surgeons of Canada or the Council on Postdoctoral Training of the American Osteopathic Association and must include training and experience specified in paragraphs 4.54.2.1 and 4.54.2.2 of this section.

**Amend 4.55 to read:**

Except as provided in RHA 4.23, the licensee shall require the authorized user of strontium‑90 for ophthalmic radiotherapy to be a physician who—

 4.55.1 Is an authorized user under RHA 4.54 or equivalent NRC requirements; or

 4.55.2 Has completed 24 hours of classroom and laboratory training applicable to the medical use of strontium‑90 for ophthalmic radiotherapy. The training must include—

 4.55.2.1 Radiation physics and instrumentation;

 4.55.2.2 Radiation protection;

 4.55.2.3 Mathematics pertaining to the use and measurement of radioactivity; and

 4.55.2.4 Radiation biology; and

 4.55.3 Supervised clinical training in ophthalmic radiotherapy under the supervision of an authorized user at a medical institution that includes the use of strontium‑90 for the ophthalmic treatment of five individuals. This supervised clinical training must involve—

 4.55.3.1 Examination of each individual to be treated;

 4.55.3.2 Calculation of the dose to be administered;

 4.55.3.3 Administration of the dose; and

 4.55.3.4 Follow up and review of each individual’s case history; and

 4.55.4 Has obtained written attestation, signed by a preceptor authorized user who meets the requirements in RHA 4.23, 4.54, 4.55, or equivalent NRC or Agreement State requirements, that the individual has satisfactorily completed the requirements in paragraphs 4.55.2 and 4.55.3 of this section and is able to independently fulfill the radiation safety‑related duties as an authorized user of strontium‑90 for ophthalmic use.

**Amend 4.56 to read:**

**RHA 4.56. Use of Sealed Sources and Medical Devices for Diagnosis.**

 4.56.1 A licensee must use only sealed sources that are not in medical devices for diagnostic medical uses if the sealed sources are approved in the Sealed Source and Device Registry for diagnostic medicine. The sealed sources may be used for diagnostic medical uses that are not explicitly listed in the Sealed Source and Device Registry but must be used in accordance with the radiation safety conditions and limitations described in the Sealed Source and Device Registry.

 4.56.2 A licensee must only use medical devices containing sealed sources for diagnostic medical uses if both the sealed sources and medical devices are approved in the Sealed Source and Device Registry for diagnostic medical uses. The diagnostic medical devices may be used for diagnostic medical uses that are not explicitly listed in the Sealed Source and Device Registry but must be used in accordance with the radiation safety conditions and limitations described in the Sealed Source and Device Registry.

 4.56.3 Sealed sources and devices for diagnostic medical uses may be used in research in accordance with an active Investigational Device Exemption (IDE) application accepted by the U.S. Food and Drug Administration provided the requirements of RHA 4.19.1 are met.

**Amend 4.57 to read:**

**RHA 4.57. Training for Use of Sealed Sources and Medical Devices for Diagnosis.**

Except as provided in RHA 4.23, the licensee shall require the authorized user of a diagnostic sealed source for use in a device authorized under RHA 4.56 to be a physician, dentist, or podiatrist who—

 4.57.1 Is certified by a medical specialty board whose certification process includes all of the requirements in RHA 4.57.3 and 4.57.4 of this section and whose certification has been recognized by the Nuclear Regulatory Commission or an Agreement State. The names of board certifications that have been recognized by the Nuclear Regulatory Commission or an Agreement State are posted on the NRC’s Medical Uses Licensee Toolkit Web page; or

 4.57.2 Is an authorized user for uses listed in RHA 4.37 or equivalent Nuclear Regulatory Commission or Agreement State requirements; or

 4.57.3 Has had 8 hours of classroom and laboratory training in basic radionuclide handling techniques specifically applicable to the use of the device. The training must include—

 4.57.3.1 Radiation physics and instrumentation;

 4.57.3.2 Radiation protection;

 4.57.3.3 Mathematics pertaining to the use and measurement of radioactivity;

 4.57.3.4 Radiation biology; and

 4.57.4 Has completed training in the use of the device for the uses requested.

**Amend 4.58 to read:**

 4.58.1 A licensee must only use sealed sources:

 4.58.1.1 Approved and as provided for in the Sealed Source and Device Registry in photon emitting remote afterloader units, teletherapy units, or gamma stereotactic radiosurgery units to deliver therapeutic doses for medical uses: or

 4.58.1.2 In research involving photon‑emitting remote afterloader units, teletherapy units, or gamma stereotactic radiosurgery units in accordance with an active Investigational Device Exemption (IDE) application accepted by the U.S. Food and Drug Administration provided the requirements of RHA 4.19.1 are met.

 4.58.2 A licensee must use photon‑emitting remote afterloader units, teletherapy units, or gamma stereotactic radiosurgery units:

 4.58.2.1 Approved in the Sealed Source and Device Registry to deliver a therapeutic dose for medical use. These devices may be used for therapeutic medical treatments that are not explicitly provided for in the Sealed Source and Device Registry, but must be used in accordance with radiation safety conditions and limitations described in the Sealed Source and Device Registry; or

 4.58.2.2 In research in accordance with an active Investigational Device Exemption (IDE) application accepted by the FDA provided the requirements of RHA 4.19.1 are met.

**Amend 4.61.4 to read:**

 4.61.4 Training and Instructions.

 4.61.4.1 Prior to the first use for patient treatment of a new unit or an existing unit with a manufacturer upgrade that affects the operation and safety of the unit, a licensee shall ensure that vendor operational and safety training is provided to all individuals who will operate the unit. The vendor operational and safety training must be provided by the device manufacturer or by an individual certified by the device manufacturer to provide the operational and safety training.

 4.61.4.2 A licensee shall provide operational and safety instructions initially and at least annually to all individuals who operate the unit at the facility, as appropriate to the individual’s assigned duties. The instructions shall include instruction in—

 4.61.4.2.1 The procedures identified in paragraph 4.61.1.4 of this section; and

 4.61.4.2.2 The operating procedures for the unit.

**Amend 4.61.7 to read:**

 4.61.7 A licensee shall retain a copy of the procedures required by RHA 4.61.1.4 and 4.61.4.2.2 of this section in accordance with RHA 4.108.

**Amend the title of 4.72 to read:**

**RHA 4.72. Full‑inspection Servicing for Teletherapy and Gamma Stereotactic Radiosurgery Units.**

**Amend 4.72.1 to read:**

 4.72.1 A licensee shall have each teletherapy unit and gamma stereotactic radiosurgery unit fully inspected and serviced during each source replacement to assure proper functioning of the source exposure mechanism and other safety components. The interval between each full‑inspection servicing shall not exceed 5 years for each teletherapy unit and shall not exceed 7 years for each gamma stereotactic radiosurgery unit.

**Amend 4.74 to read:**

Except as provided in RHA 4.23, the licensee shall require an authorized user of a sealed source for a use authorized under RHA 4.58 to be a physician who—

 4.74.1 Is certified by a medical specialty board whose certification process has been recognized by the Nuclear Regulatory Commission or an Agreement State and who meets the requirements in paragraph 4.74.3 of this section. The names of board certifications that have been recognized by the Nuclear Regulatory Commission or an Agreement State are posted on the NRC’s Medical Uses Licensee Toolkit Web page. To have its certification process recognized, a specialty board shall require all candidates for certification to:

 4.74.1.1 Successfully complete a minimum of 3 years of residency training in radiation therapy program approved by the Residency Review Committee of the Accreditation Council for Graduate Medical Education or the Royal College of Physician and Surgeons of Canada or the Committee on Post‑Graduate Training of the American Osteopathic Association; and

 4.74.1.2 Pass an examination, administered by diplomats of the specialty board, which tests knowledge and competence in radiation safety, radionuclide handling, treatment planning, quality assurance, and clinical use of stereotactic radiosurgery, remote afterloaders and external beam therapy; or

 4.74.2 Has completed a structured educational program in basic radionuclide techniques applicable to the use of a sealed source in a therapeutic medical unit that includes—

 4.74.2.1 200 hours of classroom and laboratory training in the following areas—

 4.74.2.1.1 Radiation physics and instrumentation;

 4.74.2.1.2 Radiation protection;

 4.74.2.1.3 Mathematics pertaining to the use and measurement of radioactivity; and

 4.74.2.1.4 Radiation biology; and

 4.74.2.2 500 hours of work experience, under the supervision of an authorized user who meets the requirements in RHA 4.23, 4.74, or equivalent NRC or Agreement State requirements at a medical facility that is authorized to use radioactive materials in RHA 4.58, involving—

 4.74.2.2.1 Reviewing full calibration measurements and periodic spot‑checks;

 4.74.2.2.2 Preparing treatment plans and calculating treatment doses and times;

 4.74.2.2.3 Using administrative controls to prevent a medical event involving the use of radioactive material;

 4.74.2.2.4 Implementing emergency procedures to be followed in the event of the abnormal operation of the medical unit or console;

 4.74.2.2.5 Checking and using survey meters; and

 4.74.2.2.6 Selecting the proper dose and how it is to be administered; and

 4.74.2.3 Has completed 3 years of supervised clinical experience in radiation therapy, under an authorized user who meets the requirements in RHA 4.23, 4.74, or equivalent NRC or Agreement State requirements, as part of a formal training program approved by the Residency Review Committee for Radiation Oncology of the Accreditation Council for Graduate Medical Education or the Royal College of Physicians and Surgeons of Canada or the Committee on Postdoctoral Training of the American Osteopathic Association. This experience may be obtained concurrently with the supervised work experience required by RHA 4.74.2.2; and

 4.74.2.4 Has obtained written attestation that the individual has satisfactorily completed the requirements in paragraphs 4.74.2.1, 4.74.2.2, 4.74.2.3, and 4.74.3 of this section; and is able to independently fulfill the radiation safety‑related duties as an authorized user of each type of therapeutic medical unit for which the individual is requesting authorized user status. The attestation must be obtained from either:

 4.74.2.4.1 A preceptor authorized user who meets the requirements in RHA 4.23, 4.74, or equivalent Nuclear Regulatory Commission or Agreement State requirements for the type(s) of therapeutic medical unit for which the individual is requesting authorized user status; or

 4.74.2.4.2 A residency program director who affirms in writing that the attestation represents the consensus of the residency program faculty where at least one faculty member is an authorized user who meets the requirements in RHA 4.23, 4.74, or equivalent Nuclear Regulatory Commission or Agreement State requirements, for the type(s) of therapeutic medical unit for which the individual is requesting authorized user status, and concurs with the attestation provided by the residency program director. The residency training program must be approved by the Residency Review Committee of the Accreditation Council for Graduate Medical Education or the Royal College of Physicians and Surgeons of Canada or the Council on Postdoctoral Training of the American Osteopathic Association and must include training and experience specified in paragraphs 4.74.2.1, 4.74.2.2, and 4.74.2.3 of this section.

 4.74.3 Has received training in device operation, safety procedures, and clinical use for the type(s) of use for which authorization is sought. This training requirement may be satisfied by satisfactory completion of a training program provided by the vendor for new users or by receiving training supervised by an authorized user or authorized medical physicist, as appropriate, who is authorized for the type(s) of use for which the individual is seeking authorization.

**Add 4.89.3 to read:**

 4.89.3. For each Associate Radiation Safety Officer appointed under RHA 4.13.2, the licensee shall retain, for 5 years after the Associate Radiation Safety Officer is removed from the license, a copy of the written document appointing the Associate Radiation Safety Officer signed by the licensee’s management.

**Amend 4.102 to read:**

 A licensee shall maintain a record of safety instructions required by RHA 4.41, 4.49, and the operational and safety instructions required by RHA 4.61 for 3 years. The record must include a list of the topics covered, the date of the instruction, the name(s) of the attendee(s), and the name(s) of the individual(s) who provided the instruction.

**Amend the title of 4.116 to read:**

**RHA 4.116. Records of Full‑inspection Servicing for Teletherapy and Gamma Stereotactic Radiosurgery Units.**

**Amend 4.116.1 to read:**

 4.116.1 A licensee shall maintain a record of the full‑inspection and servicing for teletherapy and gamma stereotactic radiosurgery units required by RHA 4.72 for the duration of use of the unit.

**Amend 4.117.1 to read:**

 4.117.1 A licensee shall report any event as a medical event, except for an event that results from patient intervention, in which

 4.117.1.1 The administration of radioactive material or radiation from radioactive material, except permanent implant brachytherapy, results in –

 4.117.1.1.1 A dose that differs from the prescribed dose or dose that would have resulted from the prescribed dosage by more than 0.05 Sv (5 rem) effective dose equivalent, 0.5 Sv (50 rem) to an organ or tissue, or 0.5 Sv (50 rem) shallow dose equivalent to the skin; and

 4.117.1.1.1.1 The total dose delivered differs from the prescribed dose by 20 percent or more; or

 4.117.1.1.1.2 The total dosage delivered differs from the prescribed dosage by 20 percent or more or falls outside the prescribed dosage range; or

 4.117.1.1.1.3 The fractionated dose delivered differs from the prescribed dose, for a single fraction, by 50 percent or more.

 4.117.1.1.2 A dose that exceeds 0.05 Sv (5 rem) effective dose equivalent, 0.5 Sv (50 rem) to an organ or tissue, or 0.5 Sv (50 rem) shallow dose equivalent to the skin from any of the following—

 4.117.1.1.2.1 An administration of a wrong radioactive drug containing radioactive material; or

 4.117.1.1.2.2 An administration of a radioactive drug containing radioactive material by the wrong route of administration; or

 4.117.1.1.2.3 An administration of a dose or dosage to the wrong individual or human research subject; or

 4.117.1.1.2.4 An administration of a dose or dosage delivered by the wrong mode of treatment; or

 4.117.1.1.2.5 A leaking sealed source.

 4.117.1.1.3 A dose to the skin or an organ or tissue other than the treatment site that exceeds by:

 4.117.1.1.3.1 0.5 Sv (50 rem) or more the expected dose to that site from the procedure if the administration had been given in accordance with the written directive prepared or revised before administration; and

 4.117.1.1.3.2 50 percent or more the expected dose to that site from the procedure if the administration had been given in accordance with the written directive prepared or revised before administration.

 4.117.1.2 For permanent implant brachytherapy, the administration of radioactive material or radiation from radioactive material (excluding sources that were implanted in the correct site but migrated outside the treatment site) that results in—

 4.117.1.2.1 The total source strength administered differing by 20 percent or more from the total source strength documented in the post‑implantation portion of the written directive;

 4.117.1.2.2 The total source strength administered outside of the treatment site exceeding 20 percent of the total source strength documented in the post‑implantation portion of the written directive; or

 4.117.1.2.3 An administration that includes any of the following:

 4.117.1.2.3.1 The wrong radionuclide;

 4.117.1.2.3.2 The wrong individual or human research subject;

 4.117.1.2.3.3 Sealed source(s) implanted directly into a location discontiguous from the treatment site, as documented in the post‑implantation portion of the written directive; or

 4.117.1.2.3.4 A leaking sealed source resulting in a dose that exceeds 0.5 Sv (50 rem) to an organ or tissue.

**Amend 4.117.7.1.2 to read:**

 4.117.7.1.2 Identification number or if no other identification number is available, the social security number of the individual who is the subject of the event; and

**Amend 4.118.6.1.2 to read:**

 4.118.6.1.2 Identification number or if no other identification number is available, the social security number of the individual who is the subject of the event; and

**Add 4.120 to read:**

RHA 4.120 Report and Notification for an Eluate Exceeding Permissible Molybdenum‑99, Strontium‑82, and Strontium‑85 Concentrations.

 4.120.1 The licensee shall notify by telephone the Department and the distributor of the generator within 7 calendar days after discovery that an eluate exceeded the permissible concentration listed in 4.38.1 at the time of generator elution. The telephone report to the Department must include the manufacturer, model number, and serial number (or lot number) of the generator; the results of the measurement; the date of the measurement; whether dosages were administered to patients or human research subjects, when the distributor was notified, and the action taken.

 4.120.2 By an appropriate method listed in RHA 1.13 of this chapter, the licensee shall submit a written report to the Department within 30 calendar days after discovery of an eluate exceeding the permissible concentration at the time of generator elution. The written report must include the action taken by the licensee; the patient dose assessment; the methodology used to make this dose assessment if the eluate was administered to patients or human research subjects; and the probable cause and an assessment of failure in the licensee’s equipment, procedures or training that contributed to the excessive readings if an error occurred in the licensee’s breakthrough determination; and the information in the telephone report as required by 4.120.1 of this section.

**Amend 5.14 to read:**

 5.14.1 The licensee may not permit any individual to act as a radiographer or a radiographer’s assistant unless, at all times during radiographic operations, each individual wears, on the trunk of the body, a direct reading dosimeter, an operating alarm rate meter and a personnel dosimeter. At permanent radiography facilities where other appropriate alarming or warning devices are in routine use, the wearing of an alarming rate meter is not required. Pocket dosimeters must have a range from zero to at least 200 milliroentgens and must be recharged at the start of each shift. Electronic personal dosimeters may only be used in place of ion‑chamber pocket dosimeters. Each personnel dosimeter must be assigned to and worn by only one individual. Film badges must be replaced at least monthly and all other personnel dosimeters that require replacement must be replaced at least quarterly. All personnel dosimeters must be evaluated at least quarterly or promptly after replacement, whichever is more frequent.

 5.14.2 Pocket dosimeters or electronic personal dosimeters must be read and exposures recorded at the beginning and end of each shift. The licensee shall retain each record of these exposures in accordance with RHA 5.14.7.1.

 5.14.3 Pocket dosimeters or electronic personal dosimeters shall be checked at periods not to exceed one year for correct response to radiation. Acceptable dosimeters shall read within plus or minus 20 percent of the true radiation exposure. Records must be maintained in accordance with RHA 5.14.7.1.

 5.14.4 If an individual’s pocket chamber is found to be off scale, or if his or her electronic personal dosimeter reads greater than 2 millisieverts (200 millirems), and the possibility of radiation exposure cannot be ruled out as the cause, the individual’s personnel dosimeter must be sent for processing within 24 hours. For personnel dosimeters that do not require processing, evaluation of the dosimeter must be started within 24 hours. In addition, the individual may not resume work associated with licensed material use until a determination of the individual’s radiation exposure has been made. This determination must be made by the RSO or the RSO’s designee. The results of this determination must be included in records to be maintained by the licensee until the Department terminates the license.

If the personnel dosimeter that is required by RHA 5.14.1 is lost or damaged, the worker shall cease work immediately until a replacement personnel dosimeter meeting the requirements is provided and the exposure is calculated for the time period from issuance to loss or damage of the personnel dosimeter. The results of the calculated exposure and the time period for which the personnel dosimeter was lost or damaged must be included in the records to be maintained until the Department terminates the license.

 5.14.5 Dosimetry results must be retained in accordance with RHA 5.14.7.

 5.14.6 Each alarm rate meter must:

 5.14.6.1 Be checked to ensure that the alarm functions properly (sounds) prior to use at the start of each shift;

 5.14.6.2 Be set to give an alarm signal at a preset dose rate of 500 mR/hr.;

 5.14.6.3 Require special means to change the preset alarm function; and

 5.14.6.4 Be calibrated at periods not to exceed one year for correct response to radiation: Acceptable rate meters must alarm within plus or minus 20 percent of the true radiation dose rate. Records of these calibrations must be maintained in accordance with RHA 5.14.7.2.

 5.14.7 Each licensee shall maintain the following exposure records specified in RHA 5.14:

 5.14.7.1 Direct reading dosimeter readings and yearly operability checks required by RHA 5.14.2 and 5.14.3 for 3 years after the record is made.

 5.14.7.2 Records of alarm ratemeter calibrations for 3 years after the record is made.

 5.14.7.3 Personnel dosimeter results must be retained until the Department terminates the license.

 5.14.7.4 Records of estimates of exposures as a result of: off‑scale personal direct reading dosimeters, or lost or damaged personnel dosimeters until the Department terminates the license.

**Amend 8.21.1 to read:**

 8.21.1 The licensee may not permit an individual to act as a logging supervisor or logging assistant unless that person wears a personnel dosimeter at all times during the handling of radioactive materials. Each personnel dosimeter must be assigned to and worn by only one individual. Film badges must be replaced at least monthly and other personnel dosimeters that require replacement must be replaced at least quarterly. All personnel dosimeters must be evaluated at least quarterly or promptly after replacement, whichever is more frequent.

**Amend 11.20.1 to read:**

 11.20.1 Irradiator operators shall wear a personnel dosimeter while operating a panoramic irradiator or while in the area around the pool of an underwater irradiator. The personnel dosimeter processor must be capable of detecting high energy photons in the normal and accident dose ranges. Each personnel dosimeter must be assigned to and worn by only one individual. Film badges must be processed at least monthly, and other personnel dosimeters must be processed at least quarterly. All personnel dosimeters must be evaluated at least quarterly or promptly after replacement, whichever is more frequent.

**Amend 12.5.2.2 to read:**

 12.5.2.2 Each licensee shall name one or more individuals to be reviewing officials. After completing the background investigation on the reviewing official, the licensee shall provide under oath or affirmation, a certification that the reviewing official is deemed trustworthy and reliable by the licensee. Licensees shall provide oath or affirmation certificates to the Department. The fingerprints of the named reviewing official must be taken by a law enforcement agency, Federal or State agencies that provide fingerprinting services to the public, or commercial fingerprinting services authorized by a State to take fingerprints. The licensee shall recertify that the reviewing official is deemed trustworthy and reliable every ten (10) years in accordance with RHA 12.6.3.

**Amend 12.7.3 to read:**

 12.7.3.1 For the purpose of complying with this subpart, Department licensees shall use an appropriate method listed in 10 CFR 37.7 to submit to the U.S. Nuclear Regulatory Commission, Director Division of Physical and Cyber Security Policy, 11545 Rockville Pike, ATTN: Criminal History Program, Mail Stop T‑8B20, Rockville, MD 20852, one completed, legible standard fingerprint card (Form FD‑258, ORIMDNRCOOOZ), electronic fingerprint scan or, where practicable, other fingerprint record for each individual requiring unescorted access to Category 1 or Category 2 quantities of radioactive material. Copies of these forms may be obtained by e‑mailing *MAILSVS.Resource@nrc.gov*. Guidance on submitting electronic fingerprints can be found at https://www.nrc.gov/security/chp.html.

 12.7.3.2 Fees for the processing of fingerprint checks are due upon application. Licensees shall submit payment with the application for the processing of fingerprints through corporate check, certified check, cashier’s check, money order, or electronic payment, made payable to “U.S. NRC.” (For guidance on making electronic payments, contact the Division of Physical and Cyber Security Policy by e‑mailing Crimhist.Resource@nrc.gov.) Combined payment for multiple applications is acceptable. The Commission publishes the amount of the fingerprint check application fee on the NRC’s public Web site. (To find the current fee amount, go to the Licensee Criminal History Records Check & Firearms Background Check information page at https://www.nrc.gov/security/chp.html and see the link for How do I determine how much to pay for the request?).

 12.7.3.3 The U.S. Nuclear Regulatory Commission will forward to the submitting Department licensee all data received from the FBI as a result of the licensee’s application(s) for criminal history records checks.

**Amend 12.12.4 to read:**

 12.12.4 Protection of information.

 12.12.4.1 Licensees authorized to possess Category 1 or Category 2 quantities of radioactive material shall limit access to and unauthorized disclosure of their security plan, implementing procedures, and the list of individuals that have been approved for unescorted access.

 12.12.4.2 Efforts to limit access shall include the development, implementation, and maintenance of written policies and procedures for controlling access to, and for proper handling and protection against unauthorized disclosure of, the security plan, implementing procedures, and the list of individuals that have been approved for unescorted access.

 12.12.4.3 Before granting an individual access to the security plan, implementing procedures, or the list of individuals that have been approved for unescorted access, licensees shall:

 12.12.4.3.1 Evaluate an individual’s need to know the security plan, implementing procedures, or the list of individuals that have been approved for unescorted access; and

 12.12.4.3.2 If the individual has not been authorized for unescorted access to Category 1 or Category 2 quantities of radioactive material, safeguards information, or safeguards information modified handling, the licensee must complete a background investigation to determine the individual’s trustworthiness and reliability. A trustworthiness and reliability determination shall be conducted by the reviewing official and shall include the background investigation elements contained in RHA 12.6.1.2 through 12.6.1.7.

 12.12.4.4 Licensees need not subject the following individuals to the background investigation elements for protection of information:

 12.12.4.4.1 The categories of individuals listed in RHA 12.8.1.1 through 12.8.1.13; or

 12.12.4.4.2 Security service provider employees, provided written verification that the employee has been determined to be trustworthy and reliable, by the required background investigation in RHA 12.6.1.2 through 12.6.1.7, has been provided by the security service provider.

 12.12.4.5 The licensee shall document the basis for concluding that an individual is trustworthy and reliable and should be granted access to the security plan, implementing procedures, or the list of individuals that have been approved for unescorted access.

 12.12.4.6 Licensees shall maintain a list of persons currently approved for access to the security plan, implementing procedures, or the list of individuals that have been approved for unescorted access. When a licensee determines that a person no longer needs access to the security plan, implementing procedures, or the list of individuals that have been approved for unescorted access or no longer meets the access authorization requirements for access to the information, the licensee shall remove the person from the approved list as soon as possible, but no later than 7 working days, and take prompt measures to ensure that the individual is unable to obtain the security plan, implementing procedures, or the list of individuals that have been approved for unescorted access.

 12.12.4.7 When not in use, the licensee shall store its security plan, implementing procedures, and the list of individuals that have been approved for unescorted access in a manner to prevent unauthorized access. Information stored in nonremovable electronic form must be password protected.

 12.12.4.8 The licensee shall retain as a record for 3 years after the document is no longer needed:

 12.12.4.8.1 A copy of the information protection procedures; and

 12.12.4.8.2 The list of individuals approved for access to the security plan, implementing procedures, or the list of individuals that have been approved for unescorted access.

**Amend 12.23.1.1 to read:**

 12.23.1.1 The notification must be made to the Department and to the office of each appropriate governor or governor’s designee. The contact information, including telephone numbers and mailing addresses, of governors and governors’ designees, is available on the NRC’s Web site at https://scp.nrc.gov/special/designee.pdf. A list of the contact information is also available upon request from the Director, Division of Materials Safety, Security, State, and Tribal Programs, Office of Nuclear Material Safety and Safeguards, U.S. Nuclear Regulatory Commission, Washington, DC 20555‑0001. The notification to the Department may be made by email to RAMQC\_shipments@dhec.sc.gov or by fax to 803‑898‑0391. Notifications to the Department must be to the Director, Division of Land & Waste Management, Bureau of Waste Management, 2600 Bull Street, Columbia, SC 29201.

**Statement of Need and Reasonableness:**

The following presents an analysis of the factors listed in 1976 Code Sections 1‑23‑115(C)(1)‑(3) and (9)‑(11):

DESCRIPTION OF REGULATION: 61‑63, Radioactive Materials (Title A).

Purpose: The Department proposes amending R.61‑63 to incorporate federal law as required to maintain South Carolina’s status with the United States Nuclear Regulatory Commission (“NRC”) as an Agreement State.

Legal Authority: 1976 Code Sections 13‑7‑40 et seq.

Plan for Implementation: The amendments will take legal effect upon publication in the State Register. Department personnel will then take appropriate steps to inform the regulated community of the amendments. Additionally, a copy of the regulation will be posted on the Department’s website, accessible at [www.scdhec.gov/regulations-table](http://www.scdhec.gov/regulations-table). Printed copies may also be requested, for a fee, from the Department’s Freedom of Information Office.

DETERMINATION OF NEED AND REASONABLENESS OF THE REGULATION BASED ON ALL FACTORS HEREIN AND EXPECTED BENEFITS:

The amendments are required to be implemented for South Carolina to maintain its status through the NRC as an Agreement State and to ensure compatibility with federal regulations as required by Section 274 of the Atomic Energy Act of 1954. The amendments include revisions to medical event definitions, training and experience, individual monitoring devices, social security number fraud prevention, and general overall clarifications, miscellaneous corrections, and organization.

DETERMINATION OF COSTS AND BENEFITS:

Neither the state nor its political subdivisions will incur additional costs through implementation of these amendments. Existing staff and resources will be utilized to implement the revisions to the regulation. The amendments will not create any significant additional cost to the regulated community since requirements or changes to the regulations will be substantially consistent with the current guidelines and review guidelines utilized by the Department.

UNCERTAINTIES OF ESTIMATES:

None.

EFFECT ON THE ENVIRONMENT AND PUBLIC HEALTH:

These amendments seek to ensure an effective regulatory program for radioactive material users under state jurisdiction, and protection of the public and workers from unnecessary exposure to ionizing radiation.

DETRIMENTAL EFFECT ON THE ENVIRONMENT AND PUBLIC HEALTH IF THE REGULATION IS NOT IMPLEMENTED:

There is no anticipated detrimental effect on the environment.